Illicit drug use: neurologic complications …

General Neurology

Updated 08.14.2024
Released 10.08.2008
Expires For CME 08.14.2027

Illicit drug use: neurologic complications

Authors: Michael J Schneck MD, Alexandria Pecoraro MD

See Contributor Disclosures

Editor: Matthew Lorincz MD PhD

Illicit drug use: neurologic complications

In This Article

Quick Link

Introduction

Overview

The author describes the clinical features of intoxication and withdrawal of the major illicit drugs, as well as the neurologic complications often encountered in users, including seizures, stroke, and cognitive dysfunction. During 2020, the United States continued to experience an epidemic of opioid abuse as well as recreational use of synthetic cannabinoid agents marketed as “Spice” and “K2” and these problems were exacerbated by the emergence of the COVID-19 pandemic.

Key points

	• In addition to overdose, major complications of illicit drug use include trauma, infection, seizures, stroke, persistent cognitive impairment, and teratogenic effects.
	• A seizure in an illicit drug user can have an indirect cause, such as cerebral contusion or CNS infection, or can be a manifestation of direct toxicity or withdrawal (eg, barbiNorcoturate).
	• Evidence has increasingly demonstrated that a number of drugs can cause lasting neuropsychiatric impairment.

Categories of recreational drugs

Worldwide, a large number of substances are used recreationally, some legally and some not (Table 1) (39). Two types of drug dependence may occur: (1) psychic dependence (addiction) leads to craving and drug-seeking behavior; (2) physical dependence produces somatic withdrawal symptoms. Tolerance refers to the need to increase the dose of a substance to achieve the desired effect or to prevent withdrawal. Abuse refers to recreational use of an agent despite evidence of its harmfulness.

This article deals with those drugs—other than alcohol, tobacco, and caffeine—that are most often used recreationally in North America and Europe. The prevalence of illicit drug use, varying from region to region and from decade to decade, can be only crudely estimated from household surveys and hospital statistics. For example, the U.S. Department of Health and Human Service’s National Survey on Drug Use and Health reported that in 2005 20.1% of Americans aged 18 to 25 years had used an illicit drug during the past month. In 2016, a national epidemiological survey of American adults reported a 9.9% lifetime prevalence of DSM-5 drug use disorder (not including ethanol or tobacco) (119). Also, in 2016, the U.S. Surgeon General released “Facing Addiction in America,” the first ever Surgeon General’s report on substance use and addiction. The aim of the report was to shift the perception of addiction as “a moral failing” to “a chronic brain disease.” The report covers the neurobiology of addiction as well as proposals for prevention, treatment, and support services (30; U.S. Department of Health and Human Services Office of the Surgeon General 2016).

In reviewing the clinical features of individual agents, it is important to recognize that drug abusers do not usually limit themselves to a single agent and might be simultaneously intoxicated by drug combinations or even intoxicated with one agent while withdrawing from another.

Categories of drug use

Opioids. Opioids include agonists, antagonists, and mixed agonist-antagonists (Table 2). In the past, the agent most often abused was heroin, classified by the United States Food and Drug Administration (FDA) as Schedule I (high potential for abuse, no accepted medical use). In recent decades, the U.S. and other countries have experienced an upsurge in the use of prescription opioids--especially hydromorphone, methadone, and products containing oxycodone and hydrocodone--in treating chronic, non-cancer pain (130; 319). This trend was soon followed by an epidemic of recreational use of these products (72; 131; 323). Especially popular was oxycodone (misleadingly marketed by Purdue Pharmacy as minimally addictive Oxy-Contin) (311). In California, a mixture of hydrocodone and acetaminophen (brand name “Norco”) became available as a street drug (13). In contrast to past epidemics of heroin use, recreational prescription opioid users in the United States tended to be white, non-urban, and young men and women (165; 206; 328). During this period, heroin use also surged, with the increase mostly accounted for by non-medical users of prescription opioids who found heroin cheaper and easier to obtain (57; 61; 132). From 2000 to 2015 the annual number of opioid overdoses (prescription plus illicit opioids) in the U.S. more than tripled (225; 282). Of 33,091 drug overdose deaths in the United States during 2015, 63% involved an opioid. During 2016, the number of overdose deaths rose to 63,632 (66% opioid-related), and during 2017 it rose to 72,306 (84% opioid-related) (272; 52).

Whereas the early years of the opioid epidemic were marked by transition from prescription drugs to heroin, recent years have seen the emergence of “designer opioids,” (14; 105; 157; 174; 84). Dozens of different fentanyl analogs (eg, sufentanil, alfentanil, remifentanil, carfentanil) are available throughout the United States (148). They are often mixed with other drugs, including other opioids (up to 64%), cocaine (up to 65%), cannabinoids (up to 50%); amphetamines (up to 40%), ethanol (up to 23%), benzodiazepines (up to 52%), barbiturates (up to 27%), and antidepressants (up to 49%) (105). Novel non-fentanyl opioids (eg, AH-7921, MT-45, and “U-series” drugs—U-47700, U-48800, and U-49900) are more often purchased directly. Fentanyl, fentanyl analogs, and other designer opioids are sold in powder, tablet, or liquid forms and can be swallowed, snorted, smoked, injected, administered sublingually or rectally, or vaped with an electronic cigarette (157). Fentanyl can be extracted from patches for injection, ingestion, or inhalation (158). Of 60,674 fatal opioid overdoses in the United States during 2017, 3295 involved methadone (5%), 14,958 involved natural and semisynthetic opioids (24%), 15,958 involved heroin (26%), and 29,406 involved fentanyl, fentanyl analogs, and other novel designer opioids. Fentanyl has 50 to 100 times the potency of morphine. Carfentanyl’s potency is 10,000 time that of morphine.

It is estimated that 20% of patients prescribed opioids for chronic pain become long-term users (274).

From 2017 to 2018, overall U.S. opioid deaths decreased 4.6%, but that decrease only reflects prescription opioid deaths, as there was no decrease in deaths involving illicit opioids. Two-thirds of opioid deaths during 2018 involved fentanyl analogs and non-fentanyl-related synthetic opioids (113). Fentanyl and fentanyl analogs are often present in drug samples sold as cocaine (82; 235).

During this period deaths co-occurring with benzodiazepine decreased by 5.7%, but deaths co-occurring with methamphetamine increased by 14.6% (113). Increasing use of opioids combined with psychostimulants (taken, variably, for enhancement of the high or compensation for undesired effects of the opioid) is considered the “fourth wave” (after prescription opioids, heroin, and synthetic opioids) of an ever-changing opioid crisis (62; 205; 235; 320).

Opioid overdose is a major contributor to declining life expectancy in the United States (133). From 1999 to 2018, opioid overdose accounted for nearly 450,0000 deaths in the U.S. and it is estimated that currently one American dies every 11 minutes from opioid overdose (147). The situation became even worse during the COVID-19 pandemic, reflecting a bidirectional association. Opioid use disorder carries risk for contracting and spreading COVID-19 and opioids are immunosuppressant. Lockdown became a barrier to care for individuals with opioid use disorder (175; 198).

In 2014, a position paper from the American Academy of Neurology citing lack of evidence that opioid analgesics are effective in treating non-cancer pain as well as the risk of dependence and overdose provided guidelines for prescribing opioids to non-cancer patients (99). In 2015 President Barack Obama announced a national initiative to curb the opioid epidemic, noting that four of five American heroin users had started with prescription opioids (208). The long-term efficacy of opioids for non-cancer pain is questionable; in fact, not only is chronic use often ineffective but it can create a state of hyperalgesia (203; 212). In 2016, the U.S. Centers for Disease Control and Prevention also published practice guidelines for opioid use, and many states increased regulation of opioid prescriptions by physicians (34; 103; 199; 321; 169; 269; 323). Pharmaceutical companies responded to the prescription opioid epidemic by marketing “abuse deterrent” formulations, such as adding the mu-receptor antagonist naloxone to pills, rendering them ineffective if injected. Other strategies include addition of an agent that causes aversive symptoms if injected or manufacturing oral tablets that are very difficult to crush (10; 199; 323; 244).

Escalating opioid overdose death has resulted in expanded access to naloxone and to syringe service programs (209). Naloxone is currently available over-the-counter as a nasal spray or an auto-injector. Unfortunately, whereas a lifesaving dose of naloxone in 2009 cost $1, a nasal spray in 2018 cost $150, and the auto-injector costs $4500 (283).

Loperamide, an over-the-counter anti-diarrheal with opioid agonist properties, is used to relieve opioid withdrawal as well as to produce euphoria. In addition to CNS depression, users are at risk for fatal cardiac arrhythmias (85; 312).

Persons prescribed opioids are often additionally prescribed benzodiazepines, and in 2016, responding to escalating death rates in people taking both agents, the FDA directed that a black box warning appear on the labels of all benzodiazepine and opioid products (238; 191; 105).

In Eastern Europe, a designer opioid, desomorphine, has become increasingly popular. Called Krokodil for the green-black skin lesions found on users, the injectable drug is made by cooking crushed codeine pills with household hydrocarbons such as paint thinner and gasoline (05; 250). Krokodil use spread into Western Europe, and by 2018 official cases were reported in Arizona, Missouri, Cleveland, and New York. In the United States, desomorphine, which binds to mu-, delta-, and kappa-opioid receptors, is a schedule 1 drug (04).

Kratom, obtained from a Southeast Asian tree, contains numerous alkaloids, of which mitragynine has opioid-like as well as serotonergic and noradrenergic effects. Kratom leaves can be chewed, brewed as teas, ingested as capsules, or smoked. Despite warnings by the DEA, kratom use in the U.S. was legal in most states as of 2016, and over the past several years, its popularity has steadily increased. Kratom produces stimulant effects at low doses and opioid effects at higher doses. Adverse effects include anxiety, aggression, palpitations, and seizures. Kratom combined with O-desmethyltramadol (a tramadol metabolite) is marketed as “krypton.” Routine toxicologic screens do not detect kratom. Mitragynine is addictive, and withdrawal symptoms are similar to those of opioids (250). Fatal overdose has followed ingestion of mitragynine combined with tramadol or with the decongestant propylhexedrine (250; 11; 278; 109; 66).

Public advocacy for using kratom to treat opioid withdrawal or opioid use disorder lacks supportive evidence (268).

At desired levels of intoxication, opioid agonists produce drowsy euphoria, analgesia, cough suppression, miosis, and often nausea, vomiting, sweating, pruritus, hypothermia, postural hypotension, constipation, and decreased libido. Injected or smoked, heroin produces a brief ecstatic “rush” followed usually by relaxed euphoria. Overdose causes the triad of coma, respiratory depression, and pinpoint (but reactive) pupils. In adults with respiratory depression, treatment includes ventilatory support and naloxone 2 mg intravenously repeated as needed up to 20 mg; smaller doses are given when respirations are normal. An intranasal preparation is available for first responders (148). Naloxone is short-acting, so patients receiving it require careful observation. Fentanyl, fentanyl analogs, and novel synthetic opioids require larger and often repeated doses of naloxone to reverse respiratory depression (60).

Table 2. Commonly Used Opioids

Agonist
	• Camphorated tincture of opium (paregoric) • Morphine (morphine sulfate injection) • Heroin • Methadone • Fentanyl • Hydromorphone • Codeine • Oxycodone • Hydrocodone • Dihydrocodeine (in mixtures) • Tramadol • Meperidine • Propoxyphene • Oxymorphone • Tapentadol
Antagonist
	• Naloxone • Naltrexone
Mixed agonist-antagonist
	• Pentazocine • Butorphanol • Buprenorphine • Nalbuphine

Opioid withdrawal produces irritability, lacrimation, rhinorrhea, sweating, yawning, mydriasis, myalgia, muscle spasms, piloerection, nausea, vomiting, abdominal cramps, fever, hot flashes, tachycardia, hypertension, orgasm, and intense craving. In adults, seizures and delirium are not features of opioid withdrawal and might be compared to a severe flu-like illness. Infrequently, however, opioid withdrawal can cause severe fluid loss and electrolyte abnormalities, hemodynamic instability, and death. Symptoms can usually be treated (or prevented) with methadone 10 to 30 mg once or twice daily, titrated upward as needed. Alternative opioids include the mu-receptor partial agonist buprenorphine. Evidence supports the benefit of the weak mu-receptor agonist tramadol, but as of 2021 it had not been approved for this purpose by the U.S. Food and Drug Administration and it does have abuse potential (121). The alpha-2-adrenergic receptor agonists clonidine, lofexidine, guanfacine, and tizanidine suppress norepinephrine-mediated sympathetic symptoms but do not reduce craving and can produce hypotension (290).

As a result of the current opioid abuse epidemic, the number of newborns developing neonatal abstinence syndrome has increased dramatically (303; 311). In newborns, untreated opioid withdrawal is severe, sometimes resulting in seizures or myoclonus, which, if untreated, can be fatal. Treatment is with titrated doses of an opioid (124). Clinicians favoring morphine over methadone cite morphine’s easier dose adjustment, as well as methadone’s reported association with prolonged QT interval and with somatic and brain growth reduction and delayed encephalopathy (240). In a comparative trial, the duration of treatment for neonatal opioid abstinence syndrome was shorter with buprenorphine than with morphine (171).

Psychostimulants. Psychostimulants include a number of licit and illicit agents, of which cocaine, methamphetamine, and methylenedioxymethamphetamine (MDMA, “ecstasy,” “Molly”) are the principal drugs of abuse (Table 3). In 2008, 25 million people worldwide abused amphetamines and 14 million abused cocaine. In a 2018 national survey, 1.9 million Americans aged 12 years or older reported past year methamphetamine use, and 1.1 million met diagnostic criteria for methamphetamine use disorder (ie, dependence) (294). Methamphetamine resurgence can be linked to the opioid epidemic as methamphetamine use among people with opioid use disorder increased from 18.8% in 2011 to 34.2% in 2017. Further, compared to previous years, an increasing percentage of users were injecting the drug parenterally (152; 49; 224). In 2017, among 70,237 overdose deaths in the United States, 23,139 (33%) involved cocaine, other psychostimulants, or both. Nearly three fourths of cocaine-related and one half of other psychostimulant-related overdose deaths additionally involved an opioid (156).

Table 3. Commonly Used Psychostimulants

• Dextroamphetamine
• Methamphetamine
• Ephedrine
• Pseudoephedrine
• Methylphenidate
• Phenmetrazine
• Phentermine
• Methylenedioxymethamphetamine (MDMA, “ecstasy,” “Molly”)
• Cocaine
• Cathinone, methcathinone
• Modafinil

Cocaine (which, unlike other psychostimulants, is also a local anesthetic) is an alkaloid present in the South American plant Erythroxylon coca. Most often encountered as an urban street drug, cocaine is sniffed, injected, or, as alkaloidal “crack”, smoked. Methamphetamine (“speed”), easily manufactured from commercially available pseudoephedrine, is more popular in the Midwestern and Western United States and in rural areas, where it is injected or, as “ice,” smoked. MDMA, usually taken orally, is popular on college campuses and at “rave” dance parties.

Injected or smoked cocaine or methamphetamine produces a rush subjectively different from that of opioids. Repeated use produces stereotypic activity progressing to bruxism or other dyskinesias and paranoia progressing to hallucinatory psychosis. Overdose causes delirium, tachycardia, hypertensive crisis, malignant hyperthermia, cardiac arrhythmia, myoclonus, seizures, myoglobinuria, shock, coma, and death (129; 204). Treatment includes sedation with benzodiazepines, oxygen, bicarbonate for acidosis, anticonvulsants, cooling, blood pressure control (preferably with an alpha blocker or direct vasodilator), respiratory and blood pressure support, and cardiac monitoring. (In many emergency departments, methamphetamine toxicity is treated with neuroleptics, especially haloperidol; such an approach is controversial, especially regarding evidence from animal studies that the combination of methamphetamine and haloperidol is neurotoxic.)

MDMA overdose, in the setting of frenetic dancing over many hours, carries a particular risk for both hyperthermia and hyponatremia, either of which can be fatal.

In North America and Europe there has been a sharp rise in misuse of prescription stimulant medications, especially methylphenidate (Ritalin) and amphetamine compounds (Adderall). College students use stimulants both for getting a “high” and for perceived cognitive enhancement (although use of these medications appears to be negatively associated with academic performance) (330).

Khat, a shrub indigenous to the Arabian Peninsula and East Africa, contains cathinone, a beta-keto analog of amphetamine. Khat leaves are chewed in that part of the world for their stimulant properties. Designer psychostimulants derived from cathinone are widely available in Europe and North America, purchased through the Internet as “legal highs” (92; 110). Collectively marketed as “bath salts,” available compounds include methcathinone (ephedrone), mephedrone, methylone, and methylenedioxypyrovalerone (MDPV, “Slam,” “Ivory Wave,” “Cloud 9,” “Zoom,” “”Vanilla Sky,” “Bliss”), 4-methyl-methcathinone (4-MMC, “Drone,” “Meow Meow”), 3,4-methylenedioxy-N-methylcathinone (MDMC, M1), 4-methylpentedrone (4-MPD), and eutylone (215; 250; 09; 51; 173). An analogue of MDPV, alpha-pyrrolidinovalerophenome (alpha-PVP), is marketed as “flakka” or “gravel” (168; 236). Although most synthetic cathinones are amphetamine-like in their actions, MDPV and alpha-PVP are cocaine-like in blocking dopamine and norepinephrine reuptake. Numerous fatalities have been reported (157; 177).

Methylenedioxyaminoindane (MDA-1) is a designer analogue of MDMA (106).

Benzylpiperazine is one of several designer analogs of the antihelminth piperazine. Often marketed as “legal ecstasy,” they are serotonergic and, like MDMA, have stimulant effects at low doses and hallucinogenic effects at high doses (265; 277). Combinations of synthetic piperazines are sold as “Molly” (161; 250).

Case reports describe dependence on the nonamphetamine psychostimulant modafinil (172). Reports also describe dependence on the beta-adrenergic agonist and vasopressor mephentermine (117).

Sedatives and hypnotics. Sedative drugs include barbiturates, benzodiazepines, and miscellaneous agents (Table 4). Recreational use is usually oral, with desired effects (euphoria, drowsiness), overdose (coma, respiratory depression), and withdrawal symptoms (tremor, seizures, delirium tremens) resembling what is seen with ethanol.

Benzodiazepines have less abuse potential than barbiturates and are less likely to depress respiration. When taken with opioids or ethanol, however, their margin of safety is considerably reduced. Prescription opioids combined with benzodiazepines--especially alprazolam and diazepam--have been responsible for a large percentage of overdose fatalities in the current epidemic of opioid abuse (146).

“Designer benzodiazepines” began appearing early in the 21st Century. It is estimated that worldwide over 3000 such compounds have been synthesized. In the United States from 2014 to 2017, reported exposures to designer benzodiazepines increased by 330% (50). Reasons for their growing popularity are speculative and include self-treatment of anxiety or insomnia and countering the unpleasant effects of other drugs such as psychostimulants and hallucinogens. Biological half-lives of these agents vary widely, and they can be difficult to detect using standard assays (216).

Table 4. Commonly Used Sedatives and Hypnotics

Barbiturates
	• Phenobarbital • Amobarbital • Secobarbital • Pentobarbital • Butalbital
Benzodiazepines
	• Alprazolam • Chlordiazepoxide • Diazepam • Lorazepam • Oxazepam • Temazepam • Triazolam • Clonazepam • Midazolam
Miscellaneous
	• Buspirone • Chloral hydrate • Ethchlorvynol • Glutethimide • Hydroxyzine • Meprobamate • Methaqualone (no longer produced in the United States) • Paraldehyde • Zolpidem • Zaleplon • Gamma-hydroxybutyric acid

Gamma-hydroxybutyric acid (GHB) is a popular euphoriant at “rave” parties, as are two of its precursors, gamma-butyrolactone and 1,4-butanediol (285). Often taken with ethanol, these agents are notorious as “date-rape” drugs. Overdose can cause sedation and respiratory depression or delirium and coma. Withdrawal signs resemble those of other sedatives or ethanol (333).

Numerous case reports describe gabapentin abuse, dependence, and withdrawal. Some users believe gabapentin enhances opioid effects; some believe it dampens cocaine withdrawal symptoms, which include tremor, sweating, tachycardia, hypertension, agitation, hallucinations, and seizures. In one report, gabapentin misuse occurred concomitantly with an opioid (45%), benzodiazepine (39%), ethanol (24%), or cocaine (24%) (46). Also misused is the gabapentinoid pregabalin (89). Benzodiazepines do not seem to control symptoms of gabapentin withdrawal (213).

Cannabis. The hemp plant Cannabis sativa contains more than 100 cannabinoid compounds, of which delta-9-tetrahydrocannabinol (delta-9-THC) is the principal psychoactive ingredient. Marijuana consists of cut tops and leaves of the plant. Hashish consists of the plant resin, which contains the highest concentrations of delta-9-THC (123). Marijuana or hashish can be smoked or ingested. “Dabs” refers to concentrated hash oil obtained by butane extraction of delta-9-THC from the cannabis plant. The concentrate is heated, vaporized, and inhaled, often using e-cigarette devices (188; 115).

In the brain, delta-9-THC acts at stereospecific receptors, natural ligands of which are called endocannabinoids (23). Numerous synthetic agonists and antagonists, designed by pharmaceutical companies for research purposes, are now available on the Internet for recreational use. Marketed as “Spice” or “K2,” these products are often far more potent than delta-9-THC (271; 42; 90; 74). Synthetic cannabinoids can be ingested or insufflated, but most users smoke plant material (itself often psychoactive) laced with cannabinoid (214; 306). K2 is now the second most popular illicit drug (after marijuana) among United States high school seniors (151; 162).

In the United States, pharmacological preparations of delta-9-THC (dronabinol) and a synthetic analogue (nabilone) are FDA-approved for treating nausea in patients receiving chemotherapy and wasting in patients with AIDS.

Medical marijuana laws authorize cannabis preparations (usually smoked marijuana) for a variety of disorders, including amyotrophic lateral sclerosis, Alzheimer disease, Parkinson disease, muscular dystrophy, fibromyalgia, and seizures. By 2023, 38 states and Washington D.C. had passed medical marijuana laws, and 24 states and Washington D.C. had legalized recreational marijuana. Reflecting societal permissiveness, between 2002 and 2013 past-year prevalence of marijuana use in the United States increased from 4.1% to 9.5%, and prevalence of DSM-V “marijuana use disorder” (a continuum of dependence severity) rose from 1.5% to 2.9% (134). During 2015, 22.2 million Americans were current marijuana users, and 2.6 million persons aged 12 years or older used cannabis for the first time--7100 new users each day (54). During 2018, 10.5% of Americans over 17 years of age reported using marijuana in the past month. Not surprisingly, use is highest in states with legalized recreational marijuana (114). From 1995 to 2015, the average content of cannabis increased from 4% to 12%; with legalization of recreational use, potency has run as high as 30% (07).

A 2014 systematic review from the American Academy of Neurology found evidence for efficacy of oral cannabis extracts containing combinations of delta-9-THC and the non-psychoactive cannabinoid cannabidiol (nabiximols) in treating spasticity, central pain, painful spasms, or urinary frequency in patients with multiple sclerosis (252; 304). Oral cannabis extracts are probably ineffective in treating tremor and levodopa-induced dyskinesias; evidence is lacking for benefit in Huntington disease, Tourette syndrome, cervical dystonia, and epilepsy (140; 170). Class I evidence for a benefit of smoked marijuana in any neurologic condition is similarly lacking (29; 193; 91; 332; 31). In 2016, the DEA, citing the FDA’s inability to find scientific evidence for either safety or benefit, reaffirmed its classification of marijuana as a “Schedule I” drug. Physicians “aiding and abetting” a patient’s procurement of marijuana will thus be violating the federal Controlled Substance Act as well as placing themselves in tenuous liability situations.

Epidemiologic evidence suggests that access to medical marijuana correlates with a decrease in opioid use (226).

Although animal studies demonstrated that delta-9-THC reduced the effective analgesic dose of morphine, human studies failed to demonstrate a comparable “opioid-sparing effect” (184).

Three randomized placebo-controlled trials reported benefit of cannabidiol (Epidiolex), a nonpsychoactive cannabinoid compound, in the treatment of seizures in patients with Dravet syndrome and Lennox-Gastaut syndrome (08; 300; 79; 108). These studies did not extend beyond 12 to 16 weeks. In an open label, 4-year trial of cannabidiol in children with various kinds of refractory epilepsy, cannabidiol appeared to reduce seizure frequency in 27% of patients, but 81% had adverse side-effects, “serious” in 23% (267).

Cannabidiol is now FDA-approved for the treatment of seizures associated with Lennox-Gastaut syndrome and Dravet syndrome and carries schedule 5 classification. Preclinical disease models suggest potential benefit for cannabidiol in treating chronic pain, cardiovascular disease, inflammation, autoimmunity, neurodegenerative disorders, cancer, and opioid addiction (314; 231). A randomized controlled trial found that cannabidiol reduced cue-induced craving in abstinent heroin users (142).

Cannabidiol and hemp oils, derived from Cannabis sativa with low delta-9-THC content, are available in dozens of products sold as dietary supplements.

Smoked marijuana produces relaxed euphoria, disinhibition, depersonalization, subjective time-slowing, conjunctival injection, tachycardia, and postural hypotension. Peak effects of THC are reached within a few minutes of smoking marijuana; peak effects following marijuana ingestion are reached after 1 to 3 hours. Several THC metabolites are pharmacologically active. High doses can cause agitation and hallucinatory psychosis, but fatal overdose has not been documented. Withdrawal is usually mild, with jitteriness, sleep difficulty, or headache, but psychic dependence can be marked (297). The lifetime dependence risk in marijuana users is 9%, but doubles for those who begin use before the age of 17 (compared to 32% for nicotine, 23% for heroin, 17% for cocaine, and 15% for ethanol) (29; 164). Although animals are less inclined to self-administer THC than opioids or psychostimulants, rodent and primate models document the dependence liability of cannabinoids (234).

Widespread legalization of marijuana has been accompanied by numerous reports of unintentional exposure in children, including cannabis resin, cookies, beverages, joints, medical cannabis, passive smoke, candies, and hemp oil (254; 326). Lethargy and ataxia were the most common symptoms, but some had respiratory depression requiring intubation.

Synthetic cannabinoids (“Spice,” “K2,” “Kush,” “Black Mamba,” “Bombay Blue,” “fake weed,” “Mojo,” “Cloud 9,” “Skunk,” “Joker,” “Dream,” “Crazy Clown,” “Syn,” “Haze,” “Dragon Spice”), which are up to 200 times more potent than delta-9-THC, frequently produce serious adverse effects, including psychosis, hallucinations, self-mutilation, cardiac arrhythmia, myocardial infarction, vertigo, hypertension, protracted vomiting, convulsive seizures, acute kidney injury, stroke, and death (214; 270; 275; 306; 313; 63; 67; 93; 258; 296; 12; 35; 180; 237; 297). In New York City, an outbreak of “zombie-like” behavior was caused by the synthetic cannabinoid AMB-FUBINACA (01). Similarly, withdrawal symptoms are more severe than with marijuana, and dependence liability is greater (218). Synthetic cannabinoids are not identified in toxicology screens, and there is no antidote for overdose (214).

Among the cannabinoid compounds of Cannabis sativa is delta-8-THC, which, like delta-9-THC, is psychoactive but is present in only minute amounts. During 2020, extracts of delta-8-THC became increasingly popular as recreational drugs in areas where marijuana is illegal. Products include joints, blunts, gummy bears, vaping devices, and tinctures (257).

A Cochrane review of 21 randomized controlled trials of pharmacotherapies for cannabis dependence found no or incomplete evidence of benefit in any study (222).

Hallucinogens. Dozens of hallucinogenic plants are used recreationally or ritualistically around the world. In the United States, the most popular substances—referred to as “psychedelics” or “serotonergic hallucinogens”—are mescaline from peyote cactus, psilocin and psilocybin from mushrooms, dimethyltryptamine (DMT) in ayahuasca, and the synthetic compound lysergic acid diethylamide (LSD) (308; 221; 94; 118; 19). Increasingly popular is the herb Salvia divinorum, which contains the kappa opioid receptor agonist salvinorin A (249; 250; 245). Numerous “designer” hallucinogens are available with such street names as “Fly” and “Bromodragonfly” (139). Piperazine drugs such as N-benzylpiperazine (BZP) have both stimulant and hallucinogenic properties. “2C drugs” are phenylethylamines with hallucinogenic properties, often sold as “LSD” on blotting paper, but also available as tablets or liquid preparations. An N-2 methoxybenzyl-substituted class of 2C agents is referred to as NBOMe or N-bomb (176; 327; 339).

Benzydamine is a nonsteroidal antiinflammatory agent sold without prescription as a mouthwash. When it is used orally, serotonergic properties can cause hallucinations and recreational use is described (56).

Acute effects following oral ingestion are somatic (dizziness, paresthesias, tremor), psychic (depersonalization, altered mood), and perceptual (distortion and hallucinations—usually formed and vivid). Unintended effects include paranoia and panic, and high doses can cause hypertension, seizures, and stupor, but fatalities are usually the result of accidents or suicide. Fatal overdose is described with NBOMe agents (176). “Flashbacks” consist of the spontaneous reappearance of drug symptoms days or weeks after use.

Psychedelic agents do not lead to dependence or addiction. Studies are currently assessing their possible benefit in treating pain and depression in cancer patients as well as in the treatment of alcoholism and tobacco addiction (75; 107).

Ibogaine, a hallucinogenic drug derived from an African shrub, Tabernanthe iboga, is used locally in religious ceremonies. Anecdotal reports suggest benefit in treating opioid or ethanol dependence but the drug can cause fatal cardiotoxicity. Studies are in progress to develop a nontoxic analog (47).

Inhalants. A wide variety of commercial products are sniffed or huffed, especially by adolescents, to achieve euphoria similar to ethanol intoxication (Table 5). Substances include, variably, halogenated, aliphatic, and aromatic hydrocarbons such as toluene, n-hexane, butane, and trichloroethylene, as well as nitrous oxide and amyl or butyl nitrite. Especially popular with children is “dusting,” the inhalation of Dust Off, a computer keyboard cleaner that contains d-fluoroethane (281). In the United States nitrous oxide misuse increased steadily during 2000 to 2019 and then rose more sharply during 2020, probably driven by the COVID pandemic (98; 331). Unlike ethanol, overdose of inhalants can cause hallucinations and seizures. Death can result from cardiac arrhythmia, accidents, or aspiration of vomitus. Treatment consists of respiratory and cardiac monitoring. Symptoms usually clear within a few hours. Withdrawal symptoms other than craving are unlikely.

Table 5. Inhalants

Products	Contents
Aerosols	Fluorinated hydrocarbons, propane, isobutane
Cleaning fluids, spot removers, furniture polish	Chlorinated hydrocarbons, naphtha
Glues, cements	Toluene, acetone, benzene, aliphatic acetates, n-hexane, trichloroethylene, xylene, methyl ethyl ketone
Lighter fluid	Aliphatic and aromatic hydrocarbons
Fire extinguishing agents	Bromochlorodifluoromethane
Natural gas	Methane, ethane, propane, butane
Paints, enamels, paint thinners	Toluene, methylene chloride, aliphatic acetates, benzene
Petroleum	Many aliphatic and aromatic hydrocarbons
Anesthetics (surgical supply, whipped cream dispensers)	Nitrous oxide, diethyl ether, halothane, chloroform, enflurane, trichloroethylene
“Room odorizers”	Amyl, butyl, and isobutyl nitrite

Phencyclidine. Classified as a “dissociative anesthetic,” phencyclidine (PCP, “angel dust”) is usually smoked. A related agent, ketamine, (“Jet,” “Special K”), is also used recreationally and either ingested, injected, or smoked (227). A “designer” drug, methoxetamine, has a much longer duration of action than ketamine (64). Also abused is the similarly acting drug, dextromethorphan, which is present in numerous over-the-counter cough syrups (197; 153).

Low doses of PCP cause either euphoria or dysphoria and a feeling of numbness. Higher doses cause agitation, tachycardia, hypertension, fever, ataxia, paranoid or catatonic psychosis, myoclonus, seizures, rhabdomyolysis, coma, respiratory depression, and death. Treatment includes benzodiazepines, forced diuresis, cooling, antihypertensives, anticonvulsants, and cardiorespiratory support. Withdrawal signs are mild, with tremor and nervousness, but craving occurs.

Like PCP, methoxetamine, and dextromethorphan, ketamine is an antagonist at glutamate NMDA receptors. Ketamine’s antidepressant efficacy, however, appears to have a different mechanism, not yet well-understood and remarkable for its rapid onset. Whereas tricyclic antidepressants and monoamine reuptake inhibitors take weeks to achieve symptomatic relief, ketamine’s antidepressant effects are evident within a few hours and can last over a week after a single injection (75).

Anticholinergics. The plant Datura stramonium contains atropine and scopolamine, and recreational ingestion is popular among adolescents. Intoxication produces dry mouth, decreased sweating, fever, tachycardia, and dilated unreactive pupils; overdose can progress to delirium, myoclonus, seizures, coma, and death. Treatment includes physostigmine 0.5 to 3 mg repeated as needed every 30 minutes to 2 hours, plus gastric lavage, cooling, cardiac and respiratory monitoring, and, if necessary, anticonvulsants. Neuroleptics, which have anticholinergic properties, are contraindicated. Withdrawal symptoms do not occur.

Neurologic complications of illicit agents

Trauma. Trauma, including that to the brain, spinal cord, and peripheral nerves, is common among drug abusers. It may be a consequence of the drug’s acute effects--eg, violent behavior during psychostimulant- or PCP-induced psychosis or accidents during marijuana, inhalant, sedative, anticholinergic, or LSD intoxication. Between 1999 and 2010 the prevalence of cannabinoid detection in automobile fatalities increased from 4.2% to 12.2% (33). Much trauma relates to the illegality of particular agents, involving either violent crimes committed to obtain drugs or violence intrinsic to the business methods of drug traffickers. The possibility of serious head or spinal injury must always be considered in patients brought to an emergency room for drug intoxication.

Infection. Parenteral drug users are at risk for local and systemic infections, which can affect the nervous system. Hepatitis can lead to encephalopathy or hemorrhagic stroke. Cellulitis and pyogenic myositis can spread to vertebral osteomyelitis, causing radiculopathy or myelopathy. CNS complications of bacterial or fungal endocarditis include brain infarction, brain abscess, meningitis, and rupture of septic (“mycotic”) aneurysm. Tetanus, especially affecting heroin users who inject subcutaneously (“skin-popping”), tends to be severe. Botulism can occur at injection sites or, in cocaine-sniffers, in the paranasal sinuses. Anthrax can also occur at injection sites (138). Malaria has occurred in heroin users from endemic areas.

During 2017, of the 38,739 cases of HIV infection reported to the U.S Centers for Disease Control and Prevention, 6.0% were parenteral drug users (53). Among women, HIV most often followed parenteral drug use or heterosexual contact with a drug user. Reflecting on the prescription opioid epidemic, during 2014 to 2015, a single strain of HIV infection was diagnosed in 181 patients from a small community in Indiana; using shared syringes, most had injected an extended-release formulation of the prescription opioid oxymorphone (241). Among nonparenteral drug users, psychostimulants carry risk for HIV because of risky behavior, including trading sex for drugs (78).

Drug users develop the same neurologic complications of AIDS as other groups and are particularly susceptible to syphilis and tuberculosis. Heroin and cocaine users are often immune suppressed (as are heavy drinkers), and they are at risk for unusual bacterial and fungal infections independent of HIV. Fulminant encephalopathy, most often fatal, affected HIV-infected users of cocaine with or without heroin; autopsy revealed overwhelming microglia activation in the basal ganglia, and the disorder was attributed to synergistic effect of the drugs with HIV proteins (220).

HTLV-I- and HTLV-II-associated myelopathy has been described in parenteral drug users.

Seizures. Seizures may be an indirect consequence of drug use (eg, trauma, CNS infection, stroke) or may occur as a direct result of intoxication or withdrawal. Seizures are commonly encountered during withdrawal from sedatives--barbiturates more so than benzodiazepines. With methaqualone (no longer available in the United States) and glutethimide, seizures can occur during intoxication. In animal models, opioid mu-agonists lower seizure threshold, but seizures during heroin overdose are far more likely the result of additional drug intoxication (eg, cocaine) or drug withdrawal (eg, ethanol). More epileptogenic is meperidine, a consequence of the active metabolite normeperidine. Seizures are also described in tramadol users (16). In a European data-set survey, fentanyl intoxication was much more likely to be associated with seizures than heroin intoxication, and the presence of seizures was associated with worse outcome (334).

Seizures frequently occur during psychostimulant intoxication. With methamphetamine and MDMA, other signs--delirium, fever, hypertension--are usually present. With cocaine, seizures can occur without other evidence of overdose, and they may demonstrate “kindling,” a progressively lowered seizure threshold with repeated nonescalating doses of the drug. Pharmacologically active cocaine metabolites probably account for seizures occurring 12 or more hours after drug use.

Anecdotal reports describe seizure frequency either reduced or aggravated by marijuana. Seizures are a well-recognized feature of “Spice” toxicity, however (43; 258; 334; 116). As previously noted, the non-psychoactive cannabinoid compound cannabidiol has anticonvulsant properties. A 2023 review of metaanalyses of randomized controlled trials and observational studies found high grade evidence that cannabidiol improved 50% reduction of seizures and seizure events. However, it is important to note the increased adverse effects related to the central nervous system that occur when utilizing these drugs. Namely, cannabidiol was associated with somnolence; other cannabis based medicines were also associated with visual impairment, disorientation, dizziness, sedation, and vertigo (286).

Seizures occur in up to 20% of patients presenting with piperazine toxicity (250).

Stroke. As with seizures, stroke in drug abusers may be secondary to systemic complications such as endocarditis, cardiomyopathy, trauma, or hepatitis (43). Concomitant heavy ethanol or tobacco use also increases risk. A 2023 retrospective study evaluating young adults with stroke found 41% met criteria for substance use disorder. Further, patients with heroin use disorders had significantly higher mortality rates compared to those without a heroin use disorder (261). Heroin nephropathy with uremia, hypertension, and bleeding carries risk for hemorrhagic stroke. Ischemic stroke temporally related to heroin use and in the absence of other risk factors might have an immunologic mechanism with evidence of multiple cerebral infarcts occurring in the setting of heroin-induced hypereosinophilic syndrome (28). Embolism of foreign material to the brain might also occur.

Intracerebral hemorrhage in methamphetamine and MDMA users can occur in a setting resembling heat stroke, especially at “rave” parties. Methamphetamine was also implicated in cases of systemic and CNS vasculitis resembling polyarteritis nodosa. Small vessel vasculitis causing ischemic and hemorrhagic stroke was also described in amphetamine and methamphetamine users, although many of such reported cases were based on nonspecific angiographic vessel “beading.” Whereas the annual risk of intracranial saccular aneurysm rupture is less than 1% for aneurysms smaller than 7 mm, the risk of smaller aneurysms is significantly higher in methamphetamine users (223).

Over 600 cases have been reported of stroke in cocaine users, roughly half hemorrhagic and half ischemic (287; 43). Most hemorrhagic strokes are probably the result of acute surges of hypertension; in many, imaging has revealed underlying saccular aneurysm or vascular malformation. Most ischemic strokes are probably secondary to cocaine’s direct vasoconstrictive actions on cerebral vessels; vasculitis has also rarely been found. Cocaine’s effects on platelets and other coagulation factors probably contribute to stroke risk, and pharmacologically active metabolites probably account for strokes occurring hours or even days after use (280). A 2023 systematic review and metaanalysis found that stroke occurring in the setting of cocaine use was more prevalent in younger patients and those of African American descent, as well as being associated with increased odds of mortality, vasospasm, and seizure (251).

Diet pills and decongestants containing phenylpropanolamine were linked with stroke in numerous reports; as a result, the U.S. Food and Drug Administration banned these products. Similar association led to a ban on “dietary supplements” containing ephedra (“ma huang”).

LSD and PCP are vasoconstrictive, and ischemic and hemorrhagic strokes have followed use.

Anecdotal reports describe young people without other risk factors whose strokes occurred during or shortly after smoking marijuana (144; 126; 145; 335; 336). A population-based study of hospitalized patients reported an adjusted odds ratio of 1.76 for marijuana exposure associated with ischemic stroke (329). Another crossover study, after adjusting for confounders such as tobacco, found that heavy marijuana use was associated with a 3-fold increased risk of stroke or transient ischemic attack (136). A case-control study of young adults with ischemic stroke or transient ischemic attack found an odds ratio of 2.3 for marijuana use, but nearly all the patients also smoked tobacco (20). An Australian population survey, adjusting for covariates, found that subjects who used marijuana at least weekly had 4.7 times the rate of stroke compared to nonusers (136).

Proposed mechanisms for stroke in marijuana users include postural hypotension with impaired autoregulation, cardioembolism, and reversible cerebral vasoconstriction syndrome (337). “Multifocal intracranial stenosis” associated with marijuana use was reported in 10 of 48 consecutive young people with acute ischemic stroke (337).

A number of reports describe ischemic stroke in synthetic cannabinoid users (42; 101; 24; 298; 263; 232). A review of 98 cases of cannabinoid-related stroke identified 85 following marijuana use and 13 following synthetic cannabinoid use. Mean age was 32 years. Two-thirds also smoked tobacco. Eighty-seven percent of strokes were ischemic, and 8% were hemorrhagic. Half had a favorable outcome, but five patients died (336). The suggested pathophysiologic mechanism for ischemic stroke related to synthetic cannabinoid use includes hyperaggregation of platelets, cardioembolism, arrythmias, and reduction of blood supply with hypoxia. For hemorrhagic stroke, the suggested mechanism includes acute hypertension and transient vasospasm (307).

Altered mentation. Comorbid cognitive deficits are estimated to occur in 30% to 50% of those with substance use disorders and may be the result of head trauma, stroke, malnutrition, infection (including HIV encephalopathy), or concomitant ethanol abuse (211). However, whether certain drugs cause lasting cognitive or behavioral change as a direct neurotoxic effect is more difficult to determine as executive dysfunction is also a risk factor for substance use disorders. Further, pre-drug mental status is usually uncertain, and some drug users are probably self-medicating preexisting psychiatric conditions (eg, psychostimulants for depression) (55; 260). The bidirectional association between cognitive deficits and substance use is incredibly complex with a longstanding debate about the methods surrounding its study, including the relevance of animal model studies and the importance of varied exposure methods (211).

For these reasons, chronic mental abnormalities described in heroin users are open to interpretation. A meta-analysis of studies addressing “neuropsychological consequences of chronic opioid use” (including analgesia for intractable pain and methadone replacement therapy) identified significant impairments in verbal working memory and verbal fluency as well as “cognitive impulsivity,” but the authors stressed methodological problems in the studies reviewed (17). Structural and functional imaging demonstrated reduced cerebral grey matter density and decreased white matter fractional anisotropy in heroin users (324; 338). Also described are abnormal connectivity patterns in both heroin users (186) and recreational users of prescription drugs such as oxycodone and hydrocodone (309).

Neuropsychological studies, functional and structural imaging, and animal studies each provide evidence that marijuana causes lasting cognitive impairment (69; 21; 122; 22; 27; 112; 247; 291; 316; 318; 127; 37; 59; 293). In a cohort study that followed 1037 New Zealanders from age 13 years (before any used cannabis) to age 37 years, early and persistent cannabis users showed an average decline in IQ of 8 points compared with nonusers; the difference persisted after adjusting for recent cannabis use or for use of alcohol, tobacco, or other drugs (210). A metaanalysis of seven cohort studies that included pre- and post-exposure measures of IQ found an average decline of 2 IQ points following exposure to cannabis in youth (246).

Given their greater potency, it is not surprising that cognitive impairment is described in users of synthetic cannabinoids (58; 74; 59; 187).

Neuroimaging studies in cannabis users describe reduced cortical and hippocampal grey matter volume, perhaps reflecting reported abnormalities in time estimation, attention, working memory, cognitive flexibility, decision making, and psychomotor speed (15; 202; 189; 76; 68; 81; 70; 262; 96; 259; 190; 230; 325). Diffusion-weighted MRI and connectivity mapping demonstrate microstructural alterations affecting axonal pathways in long-term marijuana users (341). Children and adolescents are especially vulnerable (41). In a human twin study, decreased amygdala volume in marijuana users was likely the result of genetic or environmental factors, whereas reduced ventral striatal volume seemed more causally related to heavy marijuana use (233). Adolescents with cannabis use disorder showed attenuated loss of thickness in cortical association areas (ie, impaired synaptic pruning) (86). On the other hand, marijuana-using male adolescents at genetic risk for schizophrenia showed abnormally reduced cortical thickness compared to nonusers (102).

In a voxel-based morphometry study of 46 14-year-olds with only one or two instances of cannabis use, bilaterally greater gray matter volume in inferior medial temporal lobes, posterior cingulate, lingual gyri, and cerebellum was present compared to carefully matched THC-naïve controls. Longitudinal data made it unlikely that gray matter volume differences preceded cannabis use. The regions affected are major components of the brain’s endocannabinoid system (228).

Relevant to the issue of “medical marijuana,” patients with multiple sclerosis who smoke cannabis have greater cognitive impairment than those not using the drug (239).

Several epidemiological longitudinal studies offer evidence that heavy cannabis use is a significant risk factor for developing schizophrenia (95; 182; 273; 200; 248). Such studies show that cannabis use precedes psychotic symptoms, arguing against self-medication or reverse causality (315). Heavy marijuana users are also at increased risk for schizo-affective and other nonaffective psychoses. Reports on depression are conflicting (201; 137).

Although synthetic cannabinoids can cause acute psychosis, epidemiological studies such as those implicating cannabis as a risk factor for developing schizophrenia are lacking for synthetic cannabinoids (77).

Controversial is whether psychostimulants predispose to depression or if PCP predisposes to schizophrenia. Dextroamphetamine damages dopaminergic nerve terminals; MDMA damages serotonergic nerve terminals; and methamphetamine damages both dopaminergic and serotonergic nerve terminals. The degree to which the damage is reversible is uncertain, as is its correlation with cognitive dysfunction, which is well documented in heavy users of these agents (39; 217; 125; 181; 26). Methamphetamine neurotoxicity appears to correlate with oxidative stress, excitotoxicity, and neuroinflammation, causing structural and physiological changes in several brain regions of both animals and humans, as well as impaired learning (243; 340; 317).

Cocaine does not inflict such damage on nerve terminals, but lasting cognitive impairment and structural alterations in frontostriatal brain systems are described in heavy users (87; 192; 299). Cocaine-treated rats demonstrate abnormal dendritic spines on neurons in the nucleus accumbens, and in both rodents and humans, diffusion tensor imaging shows abnormal fractional anisotropy in cerebral white matter (276; 219). Heavy cocaine users have reduced grey matter volume in prefrontal cortex (88; 143). Monkeys repeatedly self-administering cocaine developed abnormal striatal myelin composition (284). Monkeys receiving modest but chronic doses of cocaine had altered cerebral gray matter densities, which correlated with impaired cognition and persisted after prolonged abstinence (150).

High doses of cocaine decrease hippocampal neurogenesis and impair working memory in rats (295). Rats self-administering cocaine had increased excitatory and decreased inhibitory neurotransmission in the hippocampus, which persisted with abstinence (159). Functional and diffusion tensor imaging studies reveal abnormalities in functional and structural connectivity especially involving frontostriatal circuits in cocaine-dependent humans compared to controls (141; 194; 195). Similar observations were reported in animals (194).

In a study of humans, reduced volume of medial frontal grey matter was related to the number of substances used (cocaine, alcohol, tobacco) rather than to a particular substance; in contrast, ventrolateral frontal grey matter reduction was specifically associated with cocaine use (155).

A review of studies describing the long-term effects of cocaine on cognitive function from 1999 to 2016 concluded, “The current evidence does not support the view that chronic cocaine use is associated with broad cognitive deficits” (100). Another review of placebo-controlled and case-control studies during the same period concluded, “Long-term effects of cocaine show an array of detrimental cognitive functions” (289).

A group of volunteers who had never used MDMA, but were likely to do so in the future, underwent neuropsychological testing and neuroimaging studies, which were repeated after 12 to 36 months. Those who had used MDMA during that interval, even in small doses, demonstrated decreased verbal memory and abnormal fractional anisotropy, and apparent diffusion coefficient in the thalamus, globus pallidus, and cerebral white matter (80). Serotonin transporter binding was decreased in the cerebral cortex of abstinent MDMA users who, although “grossly behaviorally normal,” demonstrated abnormalities on tests of attention, memory, and executive function (166).

A meta-analysis of neuroimaging studies in “stimulant-dependent individuals” found consistent reduction of prefrontal cortex gray matter, which was plausibly linked to impaired “self-regulation and self-awareness” (88). Direction of causality, however, remained open to question.

Gray matter abnormalities affecting cerebral cortex, striatum, and insula showed overlap between cocaine and methamphetamine users, but also significant regional differences in users of one or the other drug (127).

Toluene sniffers are at risk for cerebral white matter lesions and dementia. Lead encephalopathy is described in gasoline sniffers.

Fetal effects. Confounders to determining the effects of illicit drugs on intrauterine development and later cognition include ethanol or tobacco exposure, malnutrition, inadequate prenatal care, and home environment. Infants exposed in utero to heroin are reportedly small for gestational age, at risk for respiratory distress, and cognitively impaired later in life. Therapeutic opioid use during the first trimester is significantly associated with cardiac anomalies and spina bifida (36).

Studies of cocaine’s fetal effects are conflicting. Despite early alarm over an epidemic of “crack babies,” the detrimental effect of in utero cocaine exposure on cognition, although real, appears to be small (178). Neuropsychological testing reveals subtle abnormalities in executive functioning, and diffusion tensor imaging shows frontal white matter abnormalities (264; 18; 179; 183). A 10-year prospective study controlling for such confounders as additional drugs and environmental influences found that first trimester exposure to cocaine carried risk for reduced height, weight, and head circumference and for lower sociability and increased withdrawn behavior (255). Compared to controls, adolescents exposed prenatally to cocaine had significantly thinner right dorsolateral prefrontal cortex (185).

A meta-analysis of studies of newborns exposed in utero to cocaine found “clear evidence that crack cocaine contributes to adverse prenatal outcome,” including preterm delivery, placental displacement, reduced head circumference, small for gestational age, and low birth weight (83). A review of “congenital cocaine syndrome” concluded that “maternal cocaine use during pregnancy…is associated with a host of neurological and developmental abnormalities in the offspring,” including microcephaly, perinatal cerebral infarction, limb and genitourinary malformations, cognitive delay, brain abnormalities on MR diffusion tensor imaging, lower volumes of cortical grey matter, and later propensity to abuse tobacco, alcohol, or marijuana (302). Proposed mechanisms for fetal damage include compromised placental and cerebral blood flow and toxic interaction with monoaminergic synapses.

Prenatal exposure to methamphetamine is significantly associated with restricted fetal growth; depressed arousal in neonates; lower verbal memory, spatial memory, working memory, attention, and visual-motor integration in older children; and lasting metabolic and structural changes, especially involving frontostriatal circuitry (301; 266).

The endocannabinoid system is critically important in embryological development, including angiogenesis, cellular replication, and tissue differentiation (104; 03). In utero marijuana exposure is associated with decreased birth weight and length and with a variety of cognitive and behavioral abnormalities, especially impaired executive function (48; 154; 135; 149; 97; 256; 286). Prenatal exposure disrupts cytoskeletal dynamics necessary for the establishment of axonal connectivity (305). In mice, prenatal exposure to a synthetic cannabinoid resulted in major malformations including face, eyes, and brain (cortical dysplasia, exencephaly, and holoprosencephaly) (111). Collectively, animal and human studies provide evidence that although cannabis is not teratogenic in the sense of causing morphological abnormalities, it does have negative long-term effects on executive function (attention, inhibitory control, planning) (120).

In utero solvent exposure, especially toluene, is teratogenic in both animals and humans.

Miscellaneous effects. Severe sensorimotor polyneuropathy occurs in sniffers of glue containing n-hexane. Quadriplegia develops over a few weeks, and recovery is usually incomplete. Residual spasticity implicates additional CNS damage.

A number of reports have described sensorimotor polyneuropathy and brachial or lumbosacral plexopathy in heroin users (71). If drug-related, the mechanism is presumably immunologic, perhaps related to an adulterant.

Rhabdomyolysis with myoglobinuria and renal failure has followed use of heroin, methamphetamine, cocaine, and PCP (as well as ethanol). With cocaine, rhabdomyolysis can be a feature of overdose or occur without other evidence of toxicity. Treatment includes forced diuresis and urinary alkalinization.

Nitrous oxide sniffers develop myeloneuropathy clinically and pathologically indistinguishable from cobalamin deficiency. Anemia is absent, and serum vitamin B12 levels are usually normal. The disorder is caused by inactivation of the cobalamin-dependent enzyme methionine synthase.

Severe, irreversible parkinsonism developed in Californians injecting a street analog of meperidine contaminated with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), a metabolite of which is toxic to neurons in the substantia nigra. Symptoms responded to levodopa, but typical side effects including dyskinesias were prominent, and attempts to wean off dopaminergic therapy were unsuccessful.

“Chasing the dragon” refers to heating heroin on metal foil and inhaling the vapor through a straw or tube. A devastating spongiform leukoencephalopathy occurs in heroin users practicing this technique. Apathy and ataxia rapidly progress to varying combinations of dystonia, spastic quadriparesis, blindness, myoclonus, pseudobulbar palsy, and, in some cases, death. Neither the responsible toxin nor the pathophysiological mechanism has been identified (65; 02). A similar spongiform encephalopathy has infrequently been reported after intravenous heroin (242). Case reports also describe refractory hydrocephalus in dragon chasers (45; 73). Rarely, similar demyelinating and vascular lesions have been described in cocaine users (25). A single case report describes similar leukoencephalopathy in a synthetic cannabinoid user (06).

Chronic cocaine users often develop chorea or dystonia temporally associated with use and sometimes lasting days or weeks into abstinence. Cocaine exacerbates symptoms of Tourette syndrome, and tics have appeared in previously asymptomatic users (40).

Clinical and population studies have shown that methamphetamine users are up to three times more likely to develop Parkinson disease or parkinsonism, and median age of Parkinson disease onset is 6 years earlier in methamphetamine users compared to nondrug users with Parkinson disease. Risk for Parkinson disease is not shared by users of cocaine or MDMA (181; 26).

Acute sensorineural hearing loss, often permanent, has been associated with a number of opioids, including prescription use and heroin. A proposed mechanism is cochlear ischemia (196).

Leukoencephalopathy can affect the cerebellum in toluene sniffers, producing prominent ataxia.

Cannabinoid hyperemesis syndrome has become more prevalent with increasing use of cannabis, increasing concentration of delta-9-THC in marijuana products, and increasing use of more potent synthetic cannabinoids (288; 253). In heavy chronic users, protracted severe vomiting follows drug use, lasts 1 to 2 days, recurs with further use, and disappears with abstinence (297). Pathophysiological mechanism is unclear, as is the often dramatic relief of symptoms with hot showers and baths and topical application of capsaicin.

Marijuana inhibits luteinizing and follicle-stimulating hormones, causing reversible impotence and sterility in men and menstrual irregularity in women.

In 2019, an outbreak of severe pulmonary disease affected users of electronic cigarettes and vaping products. The disorder was traced to products containing delta-9-THC plus vitamin E acetate. As of 2020, 68 deaths and over 2800 hospitalizations had been reported (297).

Ephedrone (methcathinone) manufacture involves potassium permanganate oxidation of ephedrine or pseudoephedrine. Intravenous use is associated with an irreversible parkinsonian-like extrapyramidal syndrome attributed to manganese toxicity (292).

In a case-controlled study, MDMA was an independent risk factor for sleep apnea in abstinent users (207). The mechanism is probably related to MDMA neurotoxicity affecting CNS serotonergic axons. Whether sleep apnea contributes to the cognitive impairments observed in MDMA users is unclear.

Hallucinogen users not only experience flashbacks, but the visual phenomena—geometric shapes, objects in the peripheral field, flashes of color, enhanced color intensity, trailing and stroboscopic perception of moving objects, after images, halos, and macro/micropsia—can persist for years (“hallucinogen-persisting perception disorder”) (229).

Since 2003, U.S. cocaine samples have frequently been adulterated with the immunomodulatory drug levamisole, which is currently present in up to 70% of cocaine samples in the world. A psychoactive metabolite of levamisole, aminorex, has psychostimulant properties and therefore might increase or prolong a cocaine high. Complications attributable to levamisole in cocaine users include leukopenia, cutaneous vasculitis with perinuclear antineutrophil cytoplasmic antibodies (pANCAs), and an irreversible demyelinating leukoencephalopathy (38; 322).

The endocannabinoid anandamide is metabolized by fatty acid amide hydrolase (FAAH). Inhibitors of FAAH raise endocannabinoid levels, and in animal models, treatment with such inhibitors has shown analgesic efficacy. In a phase 1 trial in humans, several subjects developed severe acute leukoencephalopathy, one case progressing to brain death (160).

“Saturday night retinopathy” refers to visual loss following drug or alcohol intoxication with prolonged direct compression of the orbit. In one reported case, there was also bilateral hippocampal ischemia and amnesia (44).

For unclear reasons the anti-vitamin K anticoagulant bradifacoum, present in rodenticides, has become a common adulterant in preparations of synthetic cannabinoids. Outbreaks of coagulopathy, including spontaneous intracranial hemorrhage with fatal outcome, have been reported (32).

Illicit drugs carry an enormous variety of other adulterants, often pharmacologically active. Reports describe acetaminophen, aminopyrine, diltiazem, diphenhydramine, phenacetin, and quetiapine. Complications include anemia, bone marrow damage, cancer, cardiac arrhythmia, hemolytic uremic syndrome, neutropenia, and renal failure (279).

References

01: Adams AJ, Banister SD, Irizarry L, Trecki J, Schwartz M, Gerona R. “Zombie” outbreak caused by the synthetic cannabinoid AMB-FUBINACA in New York. N Engl J Med 2017;376(3):235-42. PMID 27973993
02: Alambyam V, Pace J, Miller B, et al. The emerging role of inhaled heroin in the opioid epidemic: a review. JAMA Neurol 2018;75(11):1423-34. PMID 29987325
03: Alexandre J, Carmo H, Carvalho F, Silva JP. Synthetic cannabinoids and their impact on neurodevelopmental processes. Addict Biol 2020;25(2):e12824. PMID 31441196
04: Alves EA. DARK classics in chemical neurosci: Krokodil. ACS Chem Neurosci 2020;11(23):3968-78. PMID 32877160
05: Alves EA, Soares JX, Alfonso CM, et al. The harmful chemistry behind ”krokodil”: Street-like synthesis and product analysis. Forensic Sci Int 2015;257:76-82. PMID 26282512
06: Amar JY, Ruta J, Rahimian D, Dillinger RL, Katz P. Toxic leukoencephalopathy with extrapyramidal dysfunction due to synthetic cannabinoids. J Clin Neurosci 2018;58: 213-4. PMID 30327216
07: American Chemical Society. Legalizing marijuana and the new science of weed. Available at: YouTube - MarijuanaTestingACS. 2015.
08: Anderson P. AES: Cannabidiol, bioinformatics highlight epilepsy meeting. Medscape. November 30, 2016. Available at: Medscape.com. Accessed December 2016.
09: Angoa-Perez M, Anneken JH, Kuhn DM. Neurotoxicology of synthetic cathinone analogs. Curr Top Behav Neurosci 2017;32:209-30. PMID 27753008
10: Anonymous. A new abuse-deterrent opioid—Xtampza ER. Med Lett Drugs Ther 2016;58(1497):77-8. PMID 27599334
11: Anwar M, Law R, Achier J. Notes from the field: Kratom (Mitragyna speciosa) exposures reported to poison centers - United States, 2010-2015. MMWR Morb Mortal Weekly Rep 2016;65(29):748-9. PMID 27466822
12: Armenian P, Darracq M, Gevorkyan J, et al. Intoxication from the novel synthetic cannabinoids AB-PINACA and ADB-PINACA: a case series and review of the literature. Neuropharmacology 2018a;134(Pt A):82-91. PMID 29037744
13: Armenian P, Olson A, Anaya A, Kurtz A, Ruegner R, Gerona RR. Fentanyl and a novel synthetic opioid U-47700 masquerading as street “Norco” in central California: a case report. Ann Emerg Med 2017;69(1):87-90. PMID 27473610
14: Armenian P, Vo KT, Barr-Walker J, Lynch KL. Fentanyl, fentanyl analogs and novel synthetic opioids: a comprehensive review. Neuropharmacology 2018b;134(Pt A):121-32. PMID 29042317
15: Ashtari M, Cervellione K, Cottone J, Ardekani BA, Sevy S, Kumra S. Diffusion abnormalities in adolescents and young adults with a history of heavy cannabis use. J Psychiatr Res 2009;43(3):189-204. PMID 19111160
16: Babahajian A, Khoumand P, Manouchehri F, et al. Seizure prevalence and its related factors in tramadol intoxication; a brief report. Arch Acad Emerg Med 2019;7(1):e28. PMID 31432038
17: Baldacchino A, Balfour DJ, Passetti F, Humphris G, Matthews K. Neuropsychological consequences of chronic opioid use: a quantitative review and meta-analysis. Neurosci Biobehav Rev 2012;36(9):2056-68. PMID 22771335
18: Bandstra ES, Morrow CE, Mansoor E, Accornero VH. Prenatal drug exposure: infant and toddler outcomes. J Addict Dis 2010;29(2):245-58. PMID 20407980
19: Baquiran M, Al Khalili Y. Lysergic acid diethylamide toxicity. StatPearls 2021. PMID 31985997
20: Barber PA, Pridmore HM, Krishnamurthy V, et al. Cannabis, ischemic stroke, and transient ischemic attack: a case-control study. Stroke 2013;44(8):2327-9. PMID 23696547
21: Batalla A, Bhattacharyya S, Yucel M, et al. Structural and functional imaging studies in chronic cannabis users: a systematic review of adolescent and adult findings. PLoS One 2013;8(2):e55821. PMID 23390554
22: Battistella G, Fornari E, Annoni J-M, et al. Long-term effects of cannabis on brain structure. Neuropsychopharmacology 2014;39(9):2041-8. PMID 24633558
23: Benarroch EE. Synaptic effects of cannabinoids: complexity, behavioral effects, and potential clinical implications. Neurology 2014;83(21):1958-67. PMID 25339212
24: Bernson-Leung ME, Leung LY, Kumar S. Synthetic cannabis and ischemic stroke. J Stroke Cerebrovasc Dis 2014;23(5):1239-41. PMID 24119618
25: Bianco F, Iacovelli E, Tinelli E, Lepre C, Pauri F. Recurrent leukoencephalopathy in a cocaine abuser. Neurotoxiocology 2011;32(4):410-2. PMID 21435353
26: Blum K, Cadet JL, Gold MS. Psychostimulant use disorder emphasizing methamphetamine and the opioid-dopamine connection: digging out of a hypodopaminergic ditch. J Neurol Sci 2021;420:117252. PMID 33279726
27: Bolla KI, Brown K, Eldreth D, Tate K, Cadet JL. Dose-related neurocognitive effects of marijuana use. Neurology 2002;59:1337-43. PMID 12427880
28: Bolz J, Meves SH, Kara K, Reinacher-Schick A, Gold R, Krogias C. Multiple cerebral infarctions in a young patient with heroin-induced hypereosinophilic syndrome. J Neurol Sci 2015;356(1-2):193-5. PMID 26104570
29: Bostwick JM. Blurred boundaries: the therapeutics and politics of medical marijuana. Mayo Clin Proc 2012;87(2):172-86. PMID 22305029
30: Botticelli MP, Koh HK. Changing the language of addiction. JAMA 2016;316(13):1361-2. PMID 27701667
31: Bowen LL, McRae-Clark A. Therapeutic benefit of smoked cannabis in randomized placebo-controlled studies. Pharmocatherapy 2018;38(1):80-5. PMID 29178487
32: Boyack I, Opsha O. Coagulopathic hemorrhage with use of synthetic cannabinoids. Am J Emerg Med 2019:37(2):374.e3-e4. PMID 30409461
33: Brady JE, Li G. Trends in alcohol and other drugs detected in fatally injured drivers in the United States, 1999-2010. Am J Epidemiol 2014;179(6):692-9. PMID 24477748
34: Brady KT, McCauley JL, Back SE. Prescription opioid misuse, abuse, and treatment in the United States: an update. Am J Psychiatry 2016;173(1):18-26. PMID 26337039
35: Brandehoff N, Adams A, McDaniel K, Banister SD, Gerona R, Monte AA. Synthetic cannabinoid “Black Mamba” infidelity in patients presenting for emergency stabilization in Colorado: a P scan cohort. Clin Toxicol (Phila) 2018;56(3):193-8. PMID 28862050
36: Broussard CS, Rasmussen SA, Reefhuis J, et al. Maternal treatment with opioid analgesics and risk for birth defects. Am J Obstet Gynecol 2011;204(4):314.e1-11. PMID 21345403
37: Broyd SJ, van Hell HH, Beale C, Yucel M, Solowij N. Acute and chronic effects of cannabinoids on human cognition---a systematic review. Biol Psychiatry 2016;79(7):557-67. PMID 26858214
38: Brunt TM, van den Berg J, Pennings E, Venhuis B. Adverse effects of levamisole in cocaine users: a review and risk assessment. Arch Toxicol 2017;91(6):2303-13. PMID 28314885
39: Brust JC. Neurological Aspects of Substance Abuse. 2nd edition. Boston: Butterworth-Heinemann, 2004.
40: Brust JC. Substance abuse and movement disorders. Mov Disord 2010;25(13):2010-20. PMID 20721928
41: Brust JC. Cognition and cannabis: from anecdote to advanced technology. Brain 2012;135(Pt 7):2002-5. PMID 22734131
42: Brust JC. Spice, pot, and stroke. Neurology 2013;81(24):2064-5. PMID 24212392
43: Brust JCM. Stroke and substance abuse. In: Grotta JC, Albers GW, Broderick JP, et al, editors. Stroke: pathophysiology, diagnosis, and management. 6th edition. Elsevier, 2016:648-57.
44: Budhu J, Tolokh I, Boufford M, et al. A night to forget: Saturday night retinopathy and anterograde amnesia due to fentanyl overdose. Neurol Clin Pract 2019;9(2):170-2. PMID 31041135
45: Bui DH, Pace J, Manjila S, et al. Heroin inhalation complicated by refractory hydrocephalus: a novel presentation. Neurology 2015;84(20):2093-5. PMID 25904688
46: Buttram ME, Kurtz SP. Descriptions of gabapentin misuse and associated behaviors among a sample of opioid (mis)users in South Florida. J Psychoactive Drugs 2021;53(1):47-54. PMID 32748701
47: Cameron LP, Tombari RJ, Lu J, et al. A non-hallucinogenic psychedelic analogue with therapeutic potential. Nature 2021;589(7842):474-9. PMID 33299186
48: Campolongo P, Trezza V, Palmery M, Trabace L, Cuomo V. Developmental exposure to cannabinoids causes subtle and enduring neurofunctional alterations. Int Rev Neurobiol 2009;85:117-33. PMID 19607965
49: Cano M, Huang Y. Overdose deaths involving psychostimulants with abuse potential, excluding cocaine: State-level differences and the role of opioids. Drug Alcohol Dep 2021;218:108384. PMID 33158665
50: Carpenter JE, Murray BP, Dunkley C, et al. Designer benzodiazepines: a report of exposures recorded in the National Poison Data System, 2014-2017. Clin Toxicol 2018;57(4):282-6. PMID 30430874
51: Cartiser N, Sahy A, Advenier AS, et al. Fatal intoxication involving 4-methylpentedrone (4-MPD) in a context of chemsex. Forensic Sci Int 2021;319:110659. PMID 33370656
52: CDC Wonder. Overdose death rates. NIH/NIDA. August 2018; 1-9.
53: Centers for Disease Control and Prevention. Diagnosis of HIV infection in the United States and dependent areas. Available at: https://www.cdc.gov. Accessed December 2018.
54: Center for Behavioral Health Statistics and Quality. 2016 National Survey on Drug Use and Health. 2016.
55: Chen CY, Lin KM. Health consequences of illegal drug use. Curr Opin Psychiatry 2009;22(3):287-92. PMID 19378381
56: Chiappini S, Miuli A, Mosca A, et al. The benzydamine experience: a systematic review of benzydamine abuse. Clin Neuropharmacol 2021;19(10):1728-37. PMID 33441070
57: Cicero TJ, Ellis MS, Surratt HL, et al. The changing face of heroin use in the United States. A retrospective analysis of the past 50 years. JAMA Psychiatry 2014;71(7):821-6. PMID 24871348
58: Cohen K, Kapitany-Foveny M, Mama Y, et al. The effects of synthetic cannabinoids on executive function. Psychopharmacology (Berl) 2017;234(7):1121-34. PMID 28160034
59: Cohen K, Weinstein AM. Synthetic and non-synthetic cannabinoid drugs and their adverse effects--a review from public health perspective. Front Public Health 2018;6:162. PMID 29930934
60: Comer SD, Cahill CM. Fentanyl: receptor pharmacology, abuse potential, and implications for treatment. Neurosci Biobehav Rev 2019;106:49-57. PMID 30528374
61: Compton WM, Jones CM, Baldwin GT. Relationship between nonmedical prescription-opioid use and heroin use. N Engl J Med 2016;374(2):154-63. PMID 26760086
62: Compton WM, Valentino RJ, DuPont RL. Polysubstance use in the U.S. opioid crisis. Mol Psychiatry 2021;26(1):41-50. PMID 33188253
63: Cooper ZD. Adverse effects of synthetic cannabinoids: management of acute toxicity and withdrawal. Curr Psychiatry Rep 2016;18(5):52. PMID 27074934
64: Corazza O, Schifano F, Simonato P, et al. Phenomenon of new drugs on the Internet: the case of ketamine derivative methoxetamine. Hum Psychopharmacol 2012;27(2):145-9. PMID 22389078
65: Cordova JP, Balan S, Romero J, et al. “Chasing the dragon”: New knowledge for an old practice. Am J Ther 2014;21(1):52-5. PMID 21519216
66: Corkery JM, Streete P, Claridge H, et al. Characteristics of deaths associated with kratom use. J Psychopharmacol 2019;33(9):1102-23. PMID 31429622
67: Courts J, Maskill V, Gray A, Glue P. Signs and symptoms associated with synthetic cannabinoid toxicity: systematic review. Australian Psychiatry 2016;24(6):598-601. PMID 27558216
68: Cousijn J, Wiers RW, Ridderinkhof KR, van den Brink W, Veltman DJ, Goudriaan AE. Grey matter alterations associated with cannabis use: results of a VBM study in heavy cannabis users and healthy controls. Neuroimage 2012;59(4):3845-51. PMID 21982932
69: Crean RD, Crane NA, Mason BJ. An evidence bases review of acute and long-term effects of cannabis use and executive functions. J Addict Med 2011;5(1):1-8. PMID 21321675
70: Cunha PJ, Rosa PG, Ayres AM, et al. Cannabis use, cognition, and brain structure in first-episode psychosis. Schizophrenia Res 2013;147:209-15. PMID 23672820
71: Dabby R, Djaldetti R, Gilad R, et al. Acute heroin-related neuropathy. J Periph Nerv Syst 2006;11:304-9. PMID 17117938
72: Dart RC, Surratt HL, Cicero TJ, et al. Trends in opioid analgesic abuse and mortality in the United States. N Engl J Med 2015;372(3):241-8. PMID 25587948
73: Dastur CK, Chang GY. Heroin inhalation complicated by refractory hydrocephalus: a novel presentation. Neurology 2015;85(23):2083. PMID 26644052
74: Davidson C, Opacka-Juffry J, Arevalo-Martin A, Garcia-Ovejero D, Molina-Holgado E, Molina-Holgado F. Spicing up pharmacology: a review of synthetic cannabinoids from structure to adverse events. Adv Pharmacol 2017;80:135-68. PMID 28826533
75: De Gregorio D, Aguilar-Valles A, Preller KH, et al. Hallucinogens in mental health: preclinical and clinical studies on LSD, psilocybin, MDMA, and ketamine. J Neurosci 2021;41(5):891-00. PMID 33257322
76: Demirakca T, Sartorius A, Ende G, et al. Diminished gray matter in the hippocampus of cannabis users: possible protective effects of cannabidiol. Drug Alcohol Depend 2011;114(2-3):242-5. PMID 21050680
77: Deng H, Verrico CD, Kosten TR, Nielsen DA. Psychosis and synthetic cannabinoids. Psychiatry Res 2018;268;400-12. PMID 30125871
78: Des Jarlais DC, McKnight C, Arasteh K, et al. A perfect storm: crack cocaine, HSV-2, and HIV among non-injecting drug users in New York City. Subst Use Misuse 2014;49(7):783-92. PMID 24502371
79: Devinsky O, Cross JH, Laux L, et al. Trial of cannabdiol for drug-resistant seizures in the Dravet syndrome. N Engl J Med 2017;376(21):2011-20. PMID 28813226
80: de Win MM, Jager G, Booij J, et al. Sustained effects of ecstasy on the human brain: a prospective neuroimaging study in novel users. Brain 2008;131(Pt 11):2936-45. PMID 18842607
81: Dinieri JA, Hurd YL. Rat models of prenatal and adolescent cannabis exposure. Methods Mol Biol 2012;289:231-42. PMID 22231817
82: DiSalvo P, Cooper G, Tsao J, et al. Fentanyl-contaminated cocaine outbreak with laboratory confirmation In New York City in 2019. Am J Emerg Med 2021;40:103-5. PMID 33360606
83: Dos Santos JF, de Melo Bastos Cavalcante C, Barbossa FT, et al. Maternal, fetal, and neonatal consequences associated with the use of crack cocaine during the gestational period: a systematic review and meta-analysis. Arch Gynecol Obstet 2018;298(3):487-503. PMID 29951712
84: DuPont RL. A new narrative to understand the opioid epidemic. J Glob Drug Policy Pract 2018;12:1-22.
85: Eggleston W, Marraffa JM, Stork CM, et al. Notes from the field: cardiac dysrhythmias after loperamide abuse—New York, 2008-2016. MMWR Morb Mortal Wkly Rep 2016;65(45):1276-7. PMID 27855148
86: Epstein KA, Kumra S. Altered cortical maturation in adolescent cannabis users with and without schizophrenia. Schizophrenia Res 2015;162(1-3):143-52. PMID 25600549
87: Ersche KD, Barnes A, Jones PS, Morein-Zamir S, Robbins TW, Bullmore ET. Abnormal structure of frontostriatal brain systems is associated with aspects of impulsivity and compulsivity in cocaine dependence. Brain 2011;134(Pt 7):2013-24. PMID 21690575
88: Ersche KD, Williams GB, Robbins TW, Bullmore ET. Meta-analysis of structural brain abnormalities associated with stimulant drug dependence and neuroimaging of addiction vulnerability and resilience. Curr Opin Neurobiol 2013;23(4):615-24. PMID 23523373
89: Evoy KE, Sadrameli S, Contreras J, Covvey JR, Peckham AM, Morrison MD. Abuse and misuse of pregabalin and gabapentin: a systematic review update. Drugs 2021;81(1):125-56. PMID 33215352
90: Fantegrossi WE, Moran JH, Radominska-Pandya A, et al. Distinct pharmacology and metabolism of K2 synthetic cannabinoids compared to delta-9-THC: mechanism underlying greater toxicity? Life Sci 2014;97(1):45-54. PMID 24084047
91: Farrell M, Buchbinder R, Hall W. Should doctors prescribe cannabinoids? BMJ 2014;348:g2737. PMID 24760158
92: Fass JA, Fass AD, Garcia AS. Synthetic cathinones (bath salts):legal status and patterns of abuse. Ann Pharmacother 2012;46(3):436-41. PMID 22388331
93: Fattore L. Synthetic cannabinoids-further evidence supporting the relationship between cannabinoids and psychosis. Biol Psychiatry 2016:79(7):539-48. PMID 26970364
94: Feng LY, Battulga A, Han E, Chung H, Li JH. New psychoactive substances of natural origin: a brief review. J Food Drug Anal 2017;25(3):461-71. PMID 28911631
95: Fernandez-Espejo E, Viveros MP, Nunez L, Ellenbroek BA, Rodriguez de Fonseca F. Role of cannabis and endocannabinoids in the genesis of schizophrenia. Psychopharmacology (Berl) 2009;206(4):531-49. PMID 19629449
96: Filbey FM, Aslan S, Calhoun VD, et al. Long-term effects of marijuana use on the brain. Proc Natl Acad Sci U S A 2014;111(47):16913-8. PMID 25385625
97: Forray A, Foster D. Substance use in the perinatal period. Curr Psychiatry Rep 2015;17(11):91. PMID 26386836
98: Forrester MB. Nitrous oxide misuse reported to two United States data systems during 2000-2019. J Addict Dis 2021;39(1):46-53. PMID 32875958
99: Franklin GM. Opioids for chronic noncancer pain: a position paper of the American Academy of Neurology. Neurology 2014;83:1277-84. PMID 25267983
100: Frazer KM, Richards Q, Keith DR. The long-term effects of cocaine use on cognitive functioning: a systematic critical review. Behav Brain Res 2018;348: 241-62. PMID 29673580
101: Freeman MJ, Rose DZ, Myers MA, Gooch CL, Bozeman AC, Burgin WS. Ischemic stroke after use of the synthetic marijuana “spice.” Neurology 2013;81(24):2090-3. PMID 24212384
102: French L, Gray C, Leonard G, et al. Early cannabis use, polygenic risk score for schizophrenia, and brain maturation in adolescence. JAMA Psychiatry 2015;72(10):1002-11. PMID 26308966
103: Frieden TR, Houry D. Reducing the risks of relief--the CDC Opioid-prescribing Guideline. N Engl J Med 2016;374(16):1501-4. PMID 26977701
104: Friedrich J, Khatib D, Parsa K, Santopietro A, Gallicano GI. The grass isn’t always greener: the effects of cannabis on embryological development. BMC Pharmacol Toxicol 2016;17(1):1-13. PMID 27680736
105: Frisoni P, Bacchio E, Bilel S, et al. Novel synthetic opioids: the pathologist’s point of view. Brain Sci 2018;8(9):E170. PMID 30200549
106: Gallagher CT, Assi S, Stair JL, et al. 5,6-Methylenedioxy-2-aminoindane: from laboratory curiosity to “legal high.” Hum Psychopharmacol 2012;27(2):106-12. PMID 22389075
107: Galvao-Coelho NL, Marx W, Gonzalez M, et al. Classic serotonergic psychedelics for mood and depressive symptoms: a meta-analysis of mood disorder patients and healthy participants. Psychopharmacology 2021;238(2):341-54. PMID 33427944
108: Gaston TE, Szaflarski JP. Cannabis for treatment of epilepsy: an update. Curr Neurol Neurosci Rep 2018;18(11):73. PMID 30194563
109: Gershman K, Timm K, Frank M, et al. Death in Colorado attributed to kratom. N Engl J Med 2019;380(1):97-8. PMID 30601742
110: Gibbons S. “Legal highs”—novel and emerging psychoactive drugs: a chemical overview for the toxicologist. Clin Toxicol (Phila) 2012;50(1):15-24. PMID 22248120
111: Gilbert MT, Sulik KK, Fish EW, Baker LK, Dehart DB, Parnell SE. Dose-dependent teratogenicity of the synthetic cannabinoid CP-55,940 in mice. Neurotoxicol Teratol 2016;58:15-22. PMID 26708672
112: Gilman JM, Kuster JK, Lee S, et al. Cannabis use is quantitatively associated with nucleus accumbens and amygdala abnormalities in young adult recreational users. J Neurosci 2014;34(16):5529-38. PMID 24741043
113: Gladden RM, O’Donnell J; Mattson CL, Seth P. Changes in opioid-involved overdose deaths by opioid type and presence of benzodiazepines, cocaine, and methamphetamine—25 states, July-December 2017 to January-June 2018. MMWR Morb Mortal Wkly Rep 2019;68(34):737-44. PMID 31465320
114: Goodman S, Wadsworth E, Leos-Toro C, Hammond D; International Cannabis Policy Study team. Prevalence and forms of cannabis use in legal vs. illegal recreational cannabis markets. Int J Drug Policy 2020;76:102658. PMID 31927413
115: Gordon T, Fine J. Cornering the suspects in vaping-associated EVALI. N Engl J Med 2020;382(8):755-6. PMID 32074424
116: Gounder K, Dunuwille J, Dunne J, Lee J, Silbert P, Lawn N. The other side of the leaf: seizures associated with synthetic cannabinoid use. Epilepsy Behav 2020;104(Pt A):106901. PMID 31958643
117: Gowda GS, Singh A, Ravi M, Math SB. Mephentermine dependence syndrome---a new emerging trend of drug abuse. Asian J Psychiatry 2015;17:101-2. PMID 26236018
118: Graddy R, Buresh ME, Rastegar DA. New and emerging illicit psychoactive substances. Med Clin North Am 2018;102(4):697-714. PMID 29933824
119: Grant BF, Saha TD, Ruan WJ, et al. Epidemiology of DSM-5 drug use disorder: results from the National Epidemiologic Survey on Alcohol and Related conditions--III. JAMA Psychiatry 2016;73(1):39-47. PMID 26580136
120: Grant KS, Petroff R, Isoherranen N, Stella N, Burbacher TM. Cannabis use during pregnancy: pharmacokinetics and effects on child development. Pharmacol Ther 2018;182:133-51. PMID 28847562
121: Green JL, Dailey-Govoni T, Butler SF. Real-world data on nonmedical use of tramadol from patients evaluated for substance abuse treatment in the NAVIPPRO Addiction Severity Index-Multimedia Version (ASI-MV) network. Drug Saf 2021;44(2):235-44. PMID 33175336
122: Greydanus DE, Hawver EK, Greydanus MM, et al. Marijuana: current concepts. Front Public Health 2013;1:42. PMID 24350211
123: Greydanus DE, Kaplan G, Baxter LE Sr, Patel DR, Feucht CL. Cannabis: the never-ending, nefarious nepenthe of the 21st century: what should the clinician know? Dis Mon 2015;61(4):118-75. PMID 25835640
124: Grossman M, Seashore C, Holmes AV. Neonatal abstinence syndrome management: a review of recent evidence. Rev Recent Clin Trials 2017;12(4):226-32. PMID 28814260
125: Guerin A, Bonomo Y, Lawrence AJ, et al. Cognition and related neural findings on methamphetamine use disorder: insights from treatment implications from schizophrenia research. Front Psychiatry 2019;10:880. PMID 31920743
126: Hackam DG. Cannabis and stroke: systematic appraisal of case reports. Stroke 2015;46(3):852-6. PMID 25700287
127: Hall MG, Alhassoon OM, Stern MJ, et al. Gray matter abnormalities in cocaine versus methamphetamine-dependent patients: a neuroimaging meta-analysis. Am J Drug Alcohol Abuse 2015;41(4):290-9. PMID 26125488
128: Hall W. What has research over the past two decades revealed about the adverse health effects of recreational cannabis use? Addiction 2015;110(1):19-35. PMID 25287883
129: Halpin LE, Collins SA, Yamamoto BK. Neurotoxicity of methamphetamine and 3,4-methylenedioxymethamphetamine. Life Sci 2014;97(1):37-44. PMID 23892199
130: Han B, Compton WM, Blanco C, Crane E, Lee J, Jones CM. Prescription opioid use, misuse, and use disorders in U.S. adults: 2015 national survey on drug use and health. Ann Intern Med 2017;167(5):293-301. PMID 28761945
131: Han B, Compton WM, Jones CM, et al. Nonmedical prescription opioid use and use disorders among adults aged 18 through 64 years in the United States, 2003-2013. JAMA 2015;314(14):1468-78. PMID 26461997
132: Harocopos A, Allen B, Paone D. Circumstances and contexts of heroin initiation following non-medical opioid analgesic use in New York City. Int J Drug Policy 2016;28:106-12. PMID 26818082
133: Harper S, Riddell CA, King NB. Declining life expectancy in the United States: missing the trees for the forest. Annu Rev Public Health 2021;42:381-403. PMID 33326297
134: Hasin DS, Saha TD, Kerridge BT, et al. Prevalence of marijuana use disorders in the United States between 2001-2002 and 2012-2013. JAMA Psychiatry 2015;72(12):1235-42. PMID 26502112
135: Hayatbakhsh MR, Flenady VJ, Gibbons KS, et al. Birth outcomes associated with cannabis use before and during pregnancy. Ped Research 2012;71(2):215-9. PMID 22258135
136: Hemachandra D, McKetin R, Cherbuin N, Anstey KJ. Heavy cannabis users at elevated risk of stroke: evidence from a general population survey. Aust NZ J Public Health 2016;40(3):226-30. PMID 26558539
137: Hengartner MP, Angst J, Ajdacic-Gross V, Rossler W. Cannabis use during adolescence and the occurrence of depression, suicidality and anxiety disorder across adulthood: findings from a longitudinal cohort study over 30 years. J Affect Disord 2020;272:98-103. PMID 32379627
138: Hicks CW, Sweeney DA, Cui X, Eichacker PQ. An overview of anthrax infection including the recently identified form of disease in injection drug users. Intensive Care Med 2012;38(7):1092-104. PMID 22527064
139: Hill SL, Thomas SH. Clinical toxicology of newer recreational drugs. Clin Toxicol (Phila) 2011;49(8):705-19. PMID 21970769
140: Hosking R, Zajicek J. Cannabis in neurology---a potted review. Nat Rev Neurol 2014;10:429-30. PMID 25002109
141: Hu Y, Salmeron BJ, Stein EA, Yang Y. Impaired functional connectivity within and between frontostriatal circuits and its association with compulsive drug use and trait impulsivity in cocaine addiction. JAMA Psychiatry 2015;72(6):584-92. PMID 25853901
142: Hurd YL, Spriggs S, Alishayev J, et al. Cannabidiol for the reduction of cue-induced craving and anxiety in drug-abstinent individuals with heroin use disorder: a double-blind randomized placebo-controlled trial. Am J Psychiatry 2019;176(11):911-22. PMID 31109198
143: Ide JS, Zhang S, Hu S, Sinha R, Mazure CM, Li CS. Cerebral gray matter volumes and low-frequency fluctuation of BOLD signals in cocaine dependence: duration of use and gender difference. Drug Alcohol Depend 2014;134:51-62. PMID 24090712
144: Inal T, Kose A, Koksal O, Armagan E, Aydin SA, Ozdemir F. Acute temporal lobe infarction in a young patient associated with marijuana abuse: an unusual cause of stroke. World J Emerg Med 2014;5(1):72-4. PMID 25215152
145: Ince B, Benbir G, Yuksel O, Koseoglu L, Uluduz D. Both hemorrhagic and ischemic stroke following high doses of cannabis consumption. Presse Med 2015;44(1):106-7. PMID 25500168
146: Jann M, Kennedy WK, Lopez G. Benzodiazepines: A major component in unintentional prescription drug overdoses with opioid analgesics. J Pharm Pract 2014;27(1):5-16. PMID 24436437
147: Jannetto PJ. The North American opioid epidemic. Ther Drug Monit 2021;43(1):1-5. PMID 33337587
148: Jannetto PJ, Helander A, Garg U, Janie GC, Goldberger B, Ketha H. The fentanyl epidemic and evolution of fentanyl analogs in the United States and the European Union. Clin Chem 2019;65(2):242-53. PMID 30305277
149: Jaques SC, Kingsbury A, Hensheke P, et al. Cannabis, the pregnant woman, and her child: weeding out the myths. J Perinatol 2014;34(6):417-24. PMID 24457255
150: Jedema HP, Song X, Aizenstein HJ, et al. Long-term cocaine self-administration produces structural brain changes that correlate with altered cognition. Biol Psychiatry 2021;89(4):376-85. PMID 33012519
151: Johnston LD, O’Malley PM, Bachman JG, Schulenberg JE. Monitoring the Future national results on adolescent drug use: overview of key findings. Ann Arbor: Institute for Social Research, The University of Michigan 2012.
152: Jones CM, Olsen EO, O’Donnell J, Mustaquim D. Resurgent methamphetamine use at treatment admission in the United States, 2008-2017. Am J Public Health 2020;110(4):509-16. PMID 32078347
153: Journey JD, Agrawal S, Stern E. Dextromethorphan toxicity. StatPearls 2021. PMID 30860737
154: Jutras-Aswad D, DiNieri JA, Harkany T, Hurd YL. Neurobiological consequences of maternal cannabis on human fetal development and its neuropsychiatric outcome. Eur Arch Psychiatry Clin Neurosci 2009;259(7):395-412. PMID 19568685
155: Kaag AM, Schulte MHJ, Jansen JM, et al. The relation between gray matter volume and the use of alcohol, tobacco, cocaine, and cannabis in male polysubstance users. Drug Alcohol Depend 2018;187:186-94. PMID 29679913
156: Kariisa M, Scholl L, Wilson N, et al. Drug overdose deaths involving cocaine and psychostimulants with abuse potential - United States, 2003-2017. MMWR 2019;68(17):388-95. PMID 31048676
157: Karila L, Lafaye G, Scocard A, Cottencin O, Benyamina A. MDPV and alpha-PVP use in humans: the twisted sisters. Neuropharmacology 2018;134(Pt A):65-72. PMID 29030166
158: Karila L, Marillier M, Chaumette B, Billieux J, Franchitto N, Benyamina A. New synthetic opioids: part of a new addiction landscape. Neurosci Biobehav Rev 2019;106:133-40. PMID 30217656
159: Keralapurath MM, Briggs SB, Wagner JJ. Cocaine self-administration induces changes in synaptic transmission and plasticity in ventral hippocampus. Addict Biol 2017;22(2):446-56. PMID 26692207
160: Kerbrat A, Ferre JC, Fillatre P, et al. Acute neurologic disorder from aninhibitor of fatty acid amide hydrolase. N Engl J Med 2016;375(18):1717-25. PMID 27806235
161: Kersten BP, McLaughlin ME. Toxicology and management of novel psychoactive drugs. J Pharm Practice 2015;28(1):50-65. PMID 25261428
162: Keyes KM, Rutherford C, Hamilton A, Palamar JJ. Age, period, and cohort effects in synthetic cannabinoid use among US adolescents, 2011-2015. Drug Alcohol Dep 2016;166:159-67. PMID 27491817
163: Khan S, Hanif A, Wilson MF. Ischaemic cardiomyopathy and embolic stroke in a young adult with suspected synthetic cannabinoid use. BMJ Case Rep 2018. PMID 29880579
164: Kilmer B. Recreational cannabis---minimizing the health risks from legalization. N Engl J Med 2017;376(8):705-7. PMID 28225673
165: King NB, Fraser V, Boikos C, Richardson R, Harper S. Determinants of increased opioid-related mortality in the United States and Canada, 1990-2013: a systematic review. Am J Public Health 2014;104(8):e32-42. PMID 24922138
166: Kish SJ, Lerch J, Furukawa Y, et al. Decreased cerebral cortical serotonin transporter binding in ecstasy users: a positron emission tomography/[11C]DASB and structural brain imaging study. Brain 2010;133(Pt 6):1779-97. PMID 20483717
167: Kleiman A, Brust JCM. Neurologic presentations of K2: a city hospital experience. Presented at 68th Annual Meeting of the American Academy of Neurology, Vancouver, Canada, April 17, 2016.
168: Kolanos R, Sakloth F, Jain AD, et al. Structural modification of the designer stimulant α-Pyrrolidinovalerophenone (α-PVP) influences potency at dopamine transporters. ACS Chem Neurosci 2015;6(10):1726-31. PMID 26217965
169: Kolodny A, Frieden TR. Ten steps the federal government should take now to reverse the opioid addiction epidemic. JAMA 2017;318(16):1537-8. PMID 29049522
170: Koppel BS, Brust JC, Fife T, et al. Systematic review: Efficacy and safety of medical marijuana in selected neurologic disorders. Report of the Guidelines Development Subcommittee of the American Academy of Neurology. Neurology 2014;82(17):1556-63. PMID 24778283
171: Kraft WK, Adeniyi-Jones SC, Chervoneva I, et al. Buprenorphine for the treatment of neonatal abstinence syndrome. N Engl J Med 2017;376(24):2341-8. PMID 28877016
172: Krishnan R, Chary KV. A rare case of modafinil dependence. J Pharmacol Pharmacother 2015;6(1):49-50. PMID 25709356
173: Krotulski AJ, Papsun DM, Chronister CW, et al. Eutylone intoxications—an emerging synthetic stimulant in forensic investigations. J Anal Toxicol 2021;45(1):8-20. PMID 33325503
174: Kuczynska K, Grzonkowski P, Kapcrzak L, Zawilska JB. Abuse of fentanyl: an emerging problem to face. Forensic Sci Int 2018;289:207-14. PMID 29902699
175: Kumar N, Janmohamed K, Nyhan K, et al. Substance use and substance use disorder, in relation to COVID-19 protocol for a scoping review. Systematic Rev 2021;10(1):48. PMID 33536070
176: Kyriakou C, Marinelli E, Frati P, et al. NBOMe: new potent hallucinogens---pharmacology, analytical methods, toxicities, fatalities: a review. Eur Rev Med Pharmacol Sci 2015;19(17):3270-81. PMID 26400534
177: La Maida N, Di Trana A, Giorgetti R, Tagliabracci A, Busardo FP, Huestis MA. A review of synthetic cathinone-related fatalities from 2017 to 2020. Ther Drug Monit 2021;43(1):52-68. PMID 32881779
178: Lambert BL, Bauer CR. Developmental and behavioral consequences of prenatal cocaine exposure: a review. J Perinatol 2012;32(11):819-28. PMID 22791278
179: Lane SD, Steinberg JL, Ma L, et al. Diffusion tensor imaging and decision making in cocaine dependence. PLoS ONE 2010;5(7):e11591. PMID 20661285
180: Langford AM, Bolton JR. Synthetic cannabinoids: variety is definitely not the spice of life. J Forensic Leg Med 2018;59:36-8. PMID 30130700
181: Lappin JM, Sara GE. Psychostimulants and the brain. Addiction 2019;114(11):2065-77. PMID 31321819
182: Le Bec PY, Fatseas M, Denis C, Lavie E, Auriacombe M. Cannabis and psychosis: search of a causal link through a critical and systematic review. Encephale 2009;35(4):377-85. PMID 19748375
183: Lebel C, Warner T, Colby J, et al. White matter microstructure abnormalities and executive function in adolescents with prenatal cocaine exposure. Psychiatry Res 2013;213(2):161-8. PMID 23769420
184: Le Foll B. Opioid-sparing effects of cannabinoids: myth or reality? Prog Neuropsychopharmacol Biol Psychiatry 2021;106:110065. PMID 32828853
185: Liu J, Lester BM, Neyzi N, et al. Regional brain morphometry and impulsivity in adolescents following prenatal exposure to cocaine and tobacco. JAMA Pediatr 2013;167(4):348-54. PMID 23400239
186: Liu J, Liang J, Qin W, et al. Dysfunctional connectivity patterns in chronic heroin users: an fMRI study. Neurosci Lett 2009;460(1):72-7. PMID 19450664
187: Livny A, Cohen K, Tik N, Tsarfaty G, Rosca P, Weinstein A. The effects of synthetic cannabinoids (SCs) on brain structure and function. Eur Psychopharmacol 2018;28:1047-57. PMID 30082140
188: Loflin M, Earleywine M. A new method of cannabis ingestion: the dangers of dabs? Addictive Behav 2014:39(10):1430-3. PMID 24930049
189: Lorenzetti V, Lubman DI, Whittle S, Solowij N, Yucel M. Structural MRI findings in long-term cannabis users: what do we know. Subst Use Misuse 2010;45(11):1787-808. PMID 20590400
190: Lorenzetti V, Solowij, Yucel M. The role of cannabinoids in neuroanatomic alterations in cannabis users. Biol Psychiatry 2016;79(7):e17-e31. PMID 26858282
191: Lowes R. Limit prescribing opioids, benzos together, FDA warns. Medscape. August 31, 2016. Available at: Medscape.com. Accessed December 2016.
192: Lucantonio F, Stalnaker TA, Shaham Y, Niv Y, Schoenbaum G. The impact of orbitofrontal dysfunction on cocaine addiction. Nat Neurosci 2012;15(3):358-66. PMID 22267164
193: Lutge EE, Gray A, Siegfried N. The medical use of cannabis for reducing morbidity and mortality in patients with HIV/AIDS. Cochrane Database Syst Rev 2013;4:CD005175. PMID 23633327
194: Ma L, Steinberg JL, Moeller FG, et al. Effect of cocaine dependence on brain connections: clinical implications. Expert Rev Neurother 2015a;15(11):1307-19. PMID 26512421
195: Ma L, Steinberg JL, Keyser-Marcus L, et al. Altered white matter in cocaine dependent subjects with traumatic brain injury: a diffusion tensor imaging study. Drug Alcohol Depend 2015b;151:128-34. PMID 25841982
196: MacDonald LE, Onsrud JE, Mullins-Hodgin R. Acute sensorineural hearing loss after abuse of an inhaled, crushed oxymorphone extended-release tablet. Pharmacotherapy 2015;35(7):e118-21. PMID 26112082
197: Majlesi N, Lee DC, Ali SS. Dextromethorphan abuse masquerading as a recurrent seizure disorder. Pediatr Emerg Care 2011;27(3):210-1. PMID 21378523
198: Mallet J, Dubertret C, Le Strat Y. Addictions in the COVID-19 era: current evidence, future perspectives a comprehensive review. Prog Neuropsychopharmacol Biol Psychiatry 2021;106:110070. PMID 32800868
199: Manchikanti L, Kaye AM, Kaye AD. Current state of opioid therapy and abuse. Curr Pain Headache Rep 2016;20(5):34. PMID 27048483
200: Manrique-Garcia E, Zammit S, Dalman C, et al. Cannabis, schizophrenia and other non-affective psychoses: 35 years of follow-up of a population-based cohort. Psychol Med 2012a;42(6):1321-8. PMID 21999906
201: Manrique-Garcia E, Zammit S, Dalman C, Hemmingsson T, Allebeck P. Cannabis use and depression: a longitudinal study of a national cohort of Swedish conscripts. BMC Psychiatry 2012b;12:112. PMID 22897939
202: Martin-Santos R, Fagundo AB, Crippa JA, et al. Neuroimaging in cannabis use: a systematic review of the literature. Psychol Med 2010;40(3):383-98. PMID 19627647
203: Martyn JAJ, Mao J, Bittner EA. Opioid tolerance in critical illness. N Engl J Med 2019;380(4):365-78. PMID 30673555
204: Matsumoto RR, Seminerio MJ, Turner RC, et al. Methamphetamine-induced toxicity: an updted review on issues related to hypothermia. Pharm Ther 2014;144(1):28-40. PMID 24836729
205: Mattson CL, Tanz LJ, Quinn K, Kariisa M, Patel P, Davis NL. Trends and geographic patterns in drug and synthetic opioid overdose deaths—United States, 2013-2019. MMWR Morb Mortal Wkly Rep 2021;70(6):202-7. PMID 33571180
206: Mazer-Amirshahi M, Mullins PM, Rasooly I, van den Anker J, Pines JM. Rising opioid prescribing in adult U.S. emergency department visits: 2001-2010. Acad Emerg Med 2014;21(3):236-43. PMID 24628748
207: McCann UD, Sgambati FP, Schwartz AR, Ricaurte GA. Sleep apnea in young abstinent recreational MDMA (“ecstasy”) consumers. Neurology 2009;73(23):2011-7. PMID 19955499
208: McCarthy M. Obama outlines plan to curb prescription drug and heroin misuse. BMJ 2015;351:h5656. PMID 26493451
209: McDonald R, Campbell ND, Strang J. Twenty years of take-home naloxone for the prevention of overdose deaths from heroin and other opioids---conception and maturation. Drug Alcohol Depend 2017;178:176-87. PMID 28654870
210: Meier MH, Caspi A, Ambler A, et al. Persistent cannabis users show neuropsychological decline from childhood to midlife. Proc Natl Acad Sci U S A 2012;109(40):E2657-64. PMID 22927402
211: Melugin PR, Nolan SO, Siciliano CA. Bidirectional causality between addiction and cognitive deficits. Int Rev Neurobiol 2021;157:371-407. PMID 33648674
212: Mercandante S, Arcuri E, Santoni A. Opioid-induced tolerance and hyperalgesia. CNS Drugs 2019;33(10):943-55. PMID 31578704
213: Mersfelder TL, Nichols WH. Gabapentin: abuse, dependence, and withdrawal. Ann Pharmacother 2016;50(3):229-33. PMID 26721643
214: Mills B, Yepes A, Nugent K. Synthetic cannabinoids. Am J Med Sci 2015;350(1):59-62. PMID 26132518
215: Miotto K, Striebel J, Cho AK, Wang C. Clinical and pharmacological aspects of bath salt use: a review of the literature and case reports. Drug Alcohol Depend 2013;132(1-2):1-12. PMID 23916320
216: Moosmann B, Auwarter V. Designer benzodiazepines: another class of new psychoactive substances. Handbook Exp Pharmacol 2018;252:383-410. PMID 30367253
217: Murphy PN, Wareing M, Fisk JE, Montgomery C. Executive working memory deficits in abstinent ecstasy/MDMA users: a critical review. Neuropsychobiology 2009;60(3-4):159-75. PMID 19893333
218: Nacca N, Vatti D, Sullivan R, Sud P, Su M, Marraffa J. The synthetic cannabinoid withdrawal syndrome. J Addict Med 2013;7(4):296-8. PMID 23609214
219: Narayana PA, Herrera JJ, Bockhorst KH, et al. Chronic cocaine administration causes extensive white matter damage in brain: diffusion tensor imaging and immunohistochemistry studies. Psychiatry Res 2014;221(3):220-30. PMID 24507117
220: Newsome SD, Johnson E, Pardo C, McArthur JC, Nath A. Fulminant encephalopathy with basal ganglia hyperintensities in HIV-infected drug users. Neurology 2011;76(9):787-94. PMID 21357830
221: Nichols DE. Psychedelics. Pharmacol Rev 2016;68(2):264-365. PMID 26841800
222: Nielson S, Gowing L, Sabioni P, LeFoll B. Pharmacotherapies for cannabis dependence. Cochrane Database Syst Rev 2019;CD008940. PMID 30687936
223: Noblett D, Hacein-Bey L, Waldau B, et al. Increased rupture risk in small intracranial aneurysms associated with methamphetamine use. Int J Neuroradiol 2021;27(1):75-80. PMID 32967503
224: Noseda R, Schmidt Y, Scholz I, et al. MDMA-related presentations to the emergency departments of the European Drug Emergencies Network plus (Euro-DEN Plus) over the four-year period 2014-2017. Clin Toxicol (Phila) 2021;59(2):131-7. PMID 32677861
225: O’Donnell JK, Gladden RM, Seth P. Trends in deaths involving heroin and synthetic opioids excluding methadone, and law enforcement drug product reports, by census region—United Sates, 2006-2015. MMWR Morb Mortal Wkly Rep 2017;66(34):897-903. PMID 28859052
226: Olfson M, Wall MM, Liu SM, Blanco C. Cannabis use and risk of prescription opioid use disorder in the United States. Am J Psychiatry 2018;175(1):47-53. PMID 28946762
227: Orhurhu VJ, Vashisht R, Claus LE, Cohen SP. Ketamine toxicity. StatPearls 2021. PMID 31082131
228: Orr C, Spechler P, Cao Z, e al. Grey matter volume differences associated with extremely low levels of cannabis use in adolescence. J Neurosci 2019;39(10):1817-27. PMID 30643026
229: Orsolini L, Papanti GD, DeBerardis D, Guirguis A, Corkery JM, Schifano F. The “Endless Trip” among NPS users: psychopathology and psychopharmacology in the hallucinogen-persisting perception disorder: a systematic review. Front Psychiatry 2017;8:240. PMID 29209235
230: Owens MM, Sweet LH, MacKillop J. Recent cannabis use is associated with smaller hippocampal volume: high-resolution segmentation of structural subfields in a large non-clinical sample. Addict Biol 2021;26(1):e12874. PMID 31991525
231: Pacher P, Kogan NM, Mechoulam R. Beyond THC and endocannabinoids. Annu Rev Pharmacol Toxicol 2020;60 637-59. PMID 31580774
232: Pacher P, Steffins S, Hasko G, Schindler TH, Kunos G.Cardiovascular effects of marijuana and synthetic cannabinoids: the good, the bad, and the ugly. Nature Rev Cardiol 2018;15(3):151-66. PMID 28905873
233: Pagliaccio D, Barch DM, Bogdan R, et al. Shared predisposition in the association between cannabis use and subcortical brain structure. JAMA Psychiatry 2015;72(10):994-1001. PMID 26308883
234: Panlilio LV, Justinova Z. Preclinical studies of cannabinoid reward, treatments for cannabis use disorder, and addiction-related effects of cannabinoid exposure. Neuropsychopharmacology 2018;43(1):116-41. PMID 28845848
235: Park JN, Rashidi E, Foti K, Zoorob M, Sherman S, Alexander GC. Fentanyl and fentanyl analogs in illicit stimulant supply: results from U.S. drug seizure data, 2011-2016. Drug Alcohol Depend 2021;218:108416. PMID 33278761
236: Patocka J, Zhao B, Wu W, et al. Flakka: new dangerous synthetic cathinone on the drug scene. Int J Mol Sci 2020;21(21):8185. PMID 33142953
237: Paul ABM, Simms L, Amini S, Paul AE. Teens and spice: a review of adolescent fatalities associated with synthetic cannabinoid use. J Forensic Sci 2018;6394):1321-4. PMID 29194599
238: Paulozzi LJ, Strickler GK, Kreiner PVV, Koris CM, Centers for Disease Control and Prevention (CDC). Controlled substance prescribing patterns—prescription behavior surveillance system, eight states, 2013. MMWR Surveill Summ 2015;64(9):1-14. PMID 26469747
239: Pavisian B, Macintosh BJ, Szilaqyi G, Staines RW, O'Connor P, Feinstein A. The effects of cannabis on cognition in MS patients: a psychometric and MRI study. Neurology 2014;82(21):1879-87. PMID 24789863
240: Peltz G, Anand KJ. Long-acting opioids for treating neonatal abstinence syndrome. A high price for a short stay? JAMA 2015;314(19):2023-4. PMID 26469386
241: Peters PJ, Pontones P, Hoover KW, et al. HIV infection linked to injection use of oxymorphone in Indiana, 2014-2015. N Engl J Med 2016;375(3):229-39. PMID 27468059
242: Pirompanich P, Chankrachang S. Intravenous heroin-associated delayed spongiform leukoencephalopathy: case report and review of the literature. J Med Assoc Thai 2015;98(7):703-8. PMID 26267994
243: Potvin S, Pelletier J, Grot S, Hebert C, Barr AM, Lecomte T. Cognitive deficits in individuals with methamphetamine use disorder: a meta-analysis. Addict Behav 2018;80:154-60. PMID 29407687
244: Pourmand A, Jasani G, Shay C, Mazer-Amirshahi M. The evolving landscape of acute pain management in the era of the opioid crisis. Curr Pain Headache Rep 2018a;22(11):73. PMID 30151792
245: Pourmand A, Mazer-Amirshahi M, Chistov S, Li A, Park M. Designer drugs: review and implications for emergency management. Hum Exp Toxicol 2018b;37(1):94-101. PMID 28764574
246: Power E, Sabherwal S, Healy C, O’Neill A, Cotter D, Cannon M. Intelligence decline following frequent or dependent cannabis use in youth: a systematic review and meta-analysis of longitudinal studies. Psychol Med 2021;51(2):194-200. PMID 33501901
247: Pujol J, Blanco-Hinojo L, Batella A, et al. Functional connectivity alterations in brain networks relevant to self-awareness in chronic cannabis users. J Psychiatr Res 2014;51:68-78. PMID 24411594
248: Radhakrishnan R, Wilkinson ST, D’Souza DC. Gone to pot---a review of the association between cannabis and psychosis. Front Psychiatry 2014;5:54. PMID 24904437
249: Ranganathan M, Schnakenberg A, Skosnik PD, et al. Dose-related behavioral, subjective, endocrine, and psychophysiological effects of the κ opioid agonist Salvinorin A in humans. Biol Psychiatry 2012;72(10):871-9. PMID 22817868
250: Rech MA, Donahey E, Cappiello Dziedzic JM, Oh L, Greenhalgh E. New drugs of abuse. Pharmacotherapy 2015;35(2):189-97. PMID 25471045
251: Rendon LF, Malta S, Leung J, Badenes R, Nozari A, Bilotta F. Cocaine and ischemic or hemorrhagic stroke: a systematic review and meta-analysis of clinical evidence. J Clin Med 2023;12(16):5207. PMID 37629248
252: Rice J, Cameron M. Cannabinoids for treatment of MS symptoms: state of the evidence. Curr Neurol Neurosci Rep 2018;18(8):50. PMID 29923025
253: Richards JR, Lapointe JM, Burillo-Putze G. Cannabinoid hyperemesis syndrome: potential mechanisms for the benefit of capsaicin and hot water hydrotherapy in treatment. Clin Toxicol (Phila) 2018;56(1):15-24. PMID 28730896
254: Richards JR, Smith NE, Moulin AK. Unintentional cannabis ingestion in children: a systematic review. J Pediatr 2017;190:142-52. PMID 28888560
255: Richardson GA, Goldschmidt L, Larkby C, Day NL. Effects of prenatal cocaine exposure on child behavior and growth at 10 years of age. Neurotoxicol Teratol 2013;40:1-8. PMID 23981277
256: Richardson KA, Hester AK, McLemore GL. Prenatal cannabis exposure—the “first hit” to the endocannabinoid system. Neurotoxicol Teratol 2016;58:5-14. PMID 27567698
257: Richtel M. Not quite pot, this high slips past most bans. The New York Times. March 1, 2021.
258: Riederer AM, Calpleman SL, Carlson RG, et al. Acute poisonings from synthetic cannabinoids---50 U.S. toxicology investigators consortium registry sites, 2010-2015. MMWR Morb Mortal Wkly Rep 2016;65(27):692-5. PMID 27413997
259: Rigucci S, Marques TR, DiForti M, et al. Effect of high-potency cannabis on corpus callosum microstructure. Psychol Med 2016;46(4):841-54. PMID 26610039
260: Rinehart L, Spencer S. Which came first: cannabis use or deficits in impulse control? Prog Neuropsychopharmacol Biol Psychiatry 2021;106:110066. PMID 32795592
261: Rizk HI, Magdy R, Emam K, Mohammed MS, Aboulfotooh AM. Substance use disorder in young adults with stroke: clinical characteristics and outcome. Acta Neurol Belg 2024;124(1):65-72. PMID 37454034
262: Rocchetti M, Crescini A, Borgwardt S, et al. Is cannabis neurotoxic for the healthy brain? A meta-analytical review of structural brain alterations in non-psychotic users. Psychiatry Clin Neurosci 2013;67(7):483-92. PMID 24118193
263: Rose DZ, Guerrero WR, Mokin MV, et al. Hemorrhagic stroke following use of the synthetic marijuana “spice.” Neurology 2015;85(13):1177-9. PMID 26320200
264: Rose-Jacobs R, Waber D, Beeghly M, et al. Intrauterine cocaine exposure and executive functioning in middle childhood. Neurotoxicol Teratol 2009;31(3):159-68. PMID 19146950
265: Rosenbaum CD, Carreiro SP, Babu KM. Here today, gone tomorrow…and back again. A review of herbal marijuana alternatives (K2, Spice), synthetic cathinones (bath salts), kratom, Salvia divinorum, methoxetamine, and piperazines. J Med Toxicol 2012;8(10):15-32. PMID 22271566
266: Roussotte FF, Bramen JE, Nunez SC, et al. Abnormal brain activation during working memory in children with prenatal exposure to drugs of abuse: the effects of methamphetamine, alcohol, and polydrug exposure. Neuroimage 2011;54(4):3067-75. PMID 21040792
267: Sands TT, Rahdari S, Oldham MS Caminha Nunes E, Tilton N, Cilio MR. Long-term safety, tolerability, and efficacy of cannabidiol in children with refractory epilepsy: results from an expanded access program in the US. CNS Drugs 2018:33(1):47-60.
268: Schimmel J, Amioka E, Rockhill K, et al. Prevalence and description of kratom (Mitragyna speciosa) use in the United States: a cross-sectional study. Addiction 2021;116(1):176-81. PMID 32285981
269: Schuchat A, Houry D, Guy GP Jr. New data on opioid use and prescribing in the United States. JAMA 2017;318(5):425-6. PMID 28687823
270: Schwartz MD, Trecki J, Edison LA, Steck AR, Arnold JK, Gerona RR. A common source outbreak of severe delirium associated with exposure to the novel synthetic cannabinoid ADB-PINACA. J Emerg Med 2015;48(5):573-80. PMID 25726258
271: Seely KA, Lapoint J, Moran JH, Fattore L. Spice drugs are more than harmless herbal blends: a review of the pharmacology and toxicology of synthetic cannabinoids. Prog Neuropsychopharmacol Biol Psychiatry 2012;39(2):234-43. PMID 22561602
272: Seth P, Scholl L, Rudd RA, Bacon S. Overdose deaths involving opioids, cocaine, and psychostimulants-United States, 2015-2016. MMWR Morb Mortal Wkly Rep 2018;67(12):349-58. PMID 29596405
273: Sewell RA, Ranganathan M, D’Souza DC. Cannabinoids and psychosis. Int Rev Psychiatry 2009;21(2):152-62. PMID 19367509
274: Shah M, Choi S. Toll-like receptor-dependent negative effects of opioids: a battle between analgesia and hyperalgesia. Front Immunol 2017;8:642. PMID 28620391
275: Shanks KG, Winston D, Heidingsfelder J, Behonick G. Case reports of synthetic cannabinoid XLR-11 associated fatalities. Forensic Sci Int 2015;252:e6-9. PMID 25979131
276: Shen HW, Toda S, Moussawi K, Bouknight A, Zahm DS, Kalivas PW. Altered dendritic spine plasticity in cocaine-withdrawn rats. J Neurosci 2009;29(9):2876-84. PMID 19261883
277: Simmler LD, Rickli A, Schramm Y, Hoener MC, Liechti ME. Pharmacological profiles of aminoindanes, piperazines, and pipradrol derivatives. Biochem Pharmacol 2014;88(2):237-44. PMID 24486525
278: Singh D, Narayanan S, Vicknasingam B. Traditional and non-traditional uses of Mitragynine (Kratom): a survey of the literature. Brain Res Bull 2016;126(Pt 1):41-6. PMID 27178014
279: Singh VM, Browne T, Montgomery J. The emerging role of toxic adulterants in street drugs in the US Illicit opioid crisis. Public Health Rep 2020;135(1):6-10. PMID 31738861
280: Siniscalchi A, Bonci A, Mercuri NB, et al. Cocaine dependence and stroke: pathogenesis and management. Curr Neurovasc Res 2015;12(2):163-72. PMID 25742568
281: Sisk MS, Hickey CN, Mycyk MB. Dusting right under our nose: difluoroethane abuse in the emergency department. Eur J Emerg Med 2012;19(2):130. PMID 22374432
282: Skolnick P. The opioid epidemic: crisis and solutions. Annu Rev Pharmacol Toxicol 2018a;58:143-59. PMID 28968188
283: Skolnick P. On the front lines of the opioid epidemic: rescue by naloxone. Eur J Pharmacol 2018b; 835:147-53. PMID 30092179
284: Smith HR, Beveridge TJ, Nader MA, et al. Regionally-specific alterations in myelin proteins in non-human primate white matter following prolonged cocaine self-administration. Drug Alcohol Depend 2014;137:143-7. PMID 24529965
285: Snead OC, Gibson KM. Gamma-hydroxybutyric acid. N Engl J Med 2005;352:2721-32. PMID 15987921
286: Solmi M, De Toffol M, Kim JY, et al. Balancing risks and benefits of cannabis use: umbrella review of meta-analyses of randomised controlled trials and observational studies. BMJ 2023;382:e072348. PMID 37648266
287: Sordo L, Indave BI, Barrio G, Degenhardt L, de la Fuente L, Bravo MJ. Cocaine use and risk of stroke: a systematic review. Drug Alcohol Dep 2014;142:1-13. PMID 25066468
288: Sorensen CJ, DeSanto K, Borgelt L, Phillips KT, Monte AA. Cannabinoid hyperemesis syndrome: diagnosis, pathophysiology, and treatment--a systematic review. J Med Toxicol 2017;13(1):71-87. PMID 28000146
289: Spronk DB, van Wel JH, Ramaekers JG, Verkes RJ. Characterizing the cognitive effects of cocaine: a comprehensive review. Neurosci Biobehav Rev 2013;37:1838-50. PMID 23876288
290: Srivastava AB, Mariani JJ, Levin FR. New directions in the treatment of opioid withdrawal. Lancet 2020;395(10241):1338-48. PMID 32563380
291: Steel RW, Miller JH, Sim DA, Day DJ. Delta-9-tetrahydrocannabinol disrupts hippocampal neuroplasticity and neurogenesis in trained, but not untrained adolescent Sprague-Dawley rats. Brain Res 2014;1548:12-9. PMID 24398456
292: Stepens A, Logina I, Liguts V, et al. A Parkinsonian syndrome in methcathinone users and the role of manganese. N Engl J Med 2008;358(10):1009-17. PMID 18322282
293: Stringfield SJ, Torregrossa MM. Disentangling the lasting effects of adolescent cannabinoid exposure. Prog Neuropsychopharmacol Biol Psychiatry 2021;104:110067. PMID 32791165
294: Substance Abuse and Mental Health Services Administration. Key substance use and mental health indicators in the United States: Results from the 2017 National Survey on Drug Use and Health (HHS Publication No. SMA 18-5068, NSDUH Series H-53). Rockville, MD: Center for Behavioral Health Statistics and Quality, Substance Abuse and Mental Health Services Administration, 2018. Accessed at:www. samhsa.gov
295: Sudai E, Croitoru O, Shaldubina A, et al. High cocaine dosage decreases neurogenesis in the hippocampus and impairs working memory. Addict Biol 2011;16(2):251-60. PMID 20731634
296: Tait RJ, Caldicott D, Mountain D, et al. A systematic review of adverse events arising from the use of synthetic cannabinoids and their associated treatment. Clin Toxicol (Phila) 2016;54(1):1-13. PMID 26567470
297: Takakuwa KM, Schears RM. The emergency department care of the cannabis and synthetic cannabinoid patient: a narrative review. Int J Emerg Med 2021;14(1):10. PMID 33568074
298: Takematsu M, Hoffman RS, Nelson LS, Schechter JM, Moran JH, Wiener SW. A case of acute cerebral ischemia following inhalation of a synthetic cannabinoid. Clin Toxicol 2014;52(9):973-5. PMID 25241766
299: Tau GZ, Marsh R, Wang Z, et al. Neural correlates of reward-based spatial learning in persons with cocaine dependence. Neuropsychopharmacology 2014;39(3):545-55. PMID 23917430
300: Thiele E, Mazurkiewicz M, Benbadis S, et al. Cannabidiol (CBD) significantly reduces drop seizure frequency In Lennox-Gastaut syndrome: Results of a randomized, double-blind, placebo-controlled trial (GWPCARE4) [abstract]. Presented at the 2016 American Epilepsy Society Annual Meeting, Houston, TX, December 2-6, 2016.
301: Thompson VB, Heiman J, Chambers JB, et al. Long-term behavioral consequences of prenatal MDMA exposure. Physiol Behav 2009;96(4-5):593-601. PMID 19162054
302: Todd D, Bonthius DJ, Johnston MV. Congenital cocaine syndrome. Medlink Neurology 2018.
303: Tolia VN, Patrick SW, Bennett MM, et al. Increasing incidence of the neonatal abstinence syndrome in U.S. neonatal ICUs. N Engl J Med 2015;372(22):2118-26. PMID 25913111
304: Torres-Moreno MC, Papaseit E, Torrens M, Farre M. Assessment of efficacy and tolerability of medicinal cannabinoids in patients with multiple sclerosis: a systematic review and meta-analysis. JAMA Netw Open 2018;1(6):e183485. PMID 30646241
305: Tortoriello G, Morris CV, Alpar A, et al. Miswiring the brain: delta-9-tetrahydrocannabiinol disrupts cortical development by inducing an SCG10/strathmin-2 degradation pathway. EMBO J 2014;33:668-85. PMID 24469251
306: Trecki J, Gerona RR, Schwartz MD. Synthetic cannabinoid-related illnesses and death. N Engl J Med 2015;373(2):103-7. PMID 26154784
307: Tsatsakis A, Docea AO, Calina D, et al. A mechanistic and pathophysiological approach for stroke associated with drugs of abuse. J Clin Med 2019;8(9):1295. PMID 31450861
308: Tyls F, Palenicek T, Horacek J. Psilocybin---summary of knowledge and new perspectives. Eur Neuropsychopharmacol 2014;24(3):342-56. PMID 24444771
309: Upadhyay J, Maleki N, Potter J, et al. Alterations in brain structure and functional connectivity in prescription opioid-dependent patients. Brain 2010;133(Pt 7):2098-114. PMID 20558415
310: U.S. Department of Health and Human Services Office of the Surgeon General. Facing addiction in America: The Surgeon General’s report on alcohol, drugs, and health. Washington, DC: HHS, November 2016.
311: Vadivelu N, Kai AM, Kodumudi V, Sramcik J, Kaye AD. The opioid crisis: a comprehensive overview. Curr Pain Headache Rep 2018;22(3):16. PMID 29476358
312: Vakkalanka JP, Chariton NP, Holstege CP. Epidemiologic trends in loperamide abuse and misuse. Ann Emerg Med 2017;69(1):73-8. PMID 27823872
313: van Amsterdam J, Brunt T, van den Brink W. The adverse health effects of synthetic cannabinoids with emphasis on psychosis-like effects. J Psychopharmacol 2015;29(3):254-63. PMID 25586398
314: Van Dolah HJ, Bauer BA, Mauck KF. Clinicians’ guide to cannabidiol and hemp oils. Mayo Clin Proc 2019;94(9):1840-51. PMID 31447137
315: van Winkel R, Kuepper R. Epidemiological, neurobiological, and genetic clues to the mechanisms linking cannabis use to risk for nonaffective psychosis. Annu Rev Clin Psychol 2014;10:767-91. PMID 24471373
316: Verrico CD, Gu H, Peterson ML, Sampson AR, Lewis DA. Repeated delta-9-tetrahydrocannabinol exposure in adolescent monkeys: persistent effects selective for spatial working memory. Am J Psychiatry 2014;171(4):416-25. PMID 24577206
317: Veschsanit N, Yang JL, Ngampremuan S, et al. Melatonin reverts methamphetamine-induced learning and memory impairments and hippocampal alterations in mice. Life Sci 2021;265:118844. PMID 33278389
318: Volkow ND, Baler RD, Compton WM, Weiss SR. Adverse health effects of marijuana use. N Engl J Med 2014;370(23):2219-27. PMID 24897085
319: Volkow N, Benveniste H, McLellan AT. Use and misuse of opioids in chronic pain. Annu Rev Med 2018;69:451-65. PMID 29029586
320: Volkow ND, Blanco C. The changing opioid crisis: development, challenges and opportunities. Mol Psychiatry 2021;26(1):218-33. PMID 32020048
321: Volkow ND, Mcmillan AT. Opioid abuse in chronic pain—misconceptions and mitigation strategies. N Engl J Med 2016;374(13):1253-63. PMID 27028915
322: Vonmoos M, Hirsiger S, Prelier KH, et al. Cognitive and neuroanatomical impairments associated with chronic exposure to levamisole contaminated cocaine. Translat Psychiatry 2018;8(1):235. PMID 30368522
323: Walsh SL, Babalonis S. The abuse potential of prescription opioids in humans---closing in on the first century of research. Curr Top Behav Neurosci 2017;34:33-58. PMID 27356522
324: Wang X, Li B, Zhou X, et al. Changes in brain gray matter in abstinent heroin addicts. Drug Alcohol Depend 2012;126(3):304-8. PMID 22717339
325: Wang Y, Zuo C, Wang W, Xu Q, Hao L. Reduction in hippocampal volumes subsequent to heavy cannabis use: a 3-year longitudinal study. Psychiatry Res 2021;295:113588. PMID 33261923
326: Wang GS, Heard K, Roosevelt G. The unintended consequences of marijuana legalization. J Pediatr 2017;190:12-13. PMID 29144239
327: Weaver MF, Hopper JA, Gunderson EW. Designer drugs 2015: assessment and management. Addict Sci Clin Pract 2015;10:8. PMID 25928069
328: Weisberg DF, Becker WC, Fiellin DA, Stannard C. Prescription opioid misuse in the United States and the United Kingdom: cautionary lessons. Int J Drug Policy 2014;25(6):1124-30. PMID 25190034
329: Westover AN, McBride S, Haley RW. Stroke in young adults who abuse amphetamines or cocaine: a population-based study of hospitalized patients. Arch Gen Psychiatry 2007;64(4):495-502. PMID 17404126
330: Weyandt LL, Oster DR, Marraccini ME, et al. Prescription stimulant medication misuse: Where are we and where do we go from here? Exp Clin Psychopharmacol 2016;24:400-14. PMID 27690507
331: Wiener RC, Waters C, Bhandari R, et al. Epidemiology and characteristics of people with injury due to volatile substance use to induce euphoria. Subst Use Misuse 2021;56(1):169-73. PMID 33090072
332: Wilkinson ST, D’Souza DC. Problems with the medicalization of marijuana. JAMA 2014;311(23):2377-8. PMID 24845238
333: Wojtowicz JM, Yarema MC, Wax PM. Withdrawal from gamma-hydroxybutyrate, 1,4-butanediol and gamma-butyrolactone: a case report and systematic review. CJEM 2008;10(1):69-74. PMID 18226321
334: Wolfe CE, Wood DM, Dines A, et al. Seizures as a complication of recreational drug use: analysis of the Euro-DEN Plus data-set. Toxicology 2019;73:183-7. PMID 30974132
335: Wolff V, Armspach JP, Lauer V, et al. Cannabis-associated stroke: myth or reality. Stroke 2013;44(2):558-63. PMID 23271508
336: Wolff V, Jouanius E. Strokes are possible complications of cannabinoids use. Epilepsy Behav 2017;70(Pt B):355-63. PMID 28237318
337: Wolff V, Lauer V, Rouyer O, et al. Cannabis use, ischemic stroke, and multifocal intracranial vasoconstriction: a prospective study in 48 consecutive young patients. Stroke 2011;42(6):1778-80. PMID 21512186
338: Wollman SC, Alhassoon OM, Stern MJ, et al. White mater abnormalities in long-term heroin users: a preliminary neuroimaging meta-analysis. Am J Drug Alcohol Abuse 2015;41(2):133-8. PMID 25664621
339: Wood DM, Sedefov R, Cunningham A, Dargan PI. Prevalence of use and acute toxicity associated with the use of NBOMe drugs. Clin Toxicol 2015;53(2):85-92. PMID 25658166
340: Yang X, Wang Y, Li Q, et al. The main molecular mechanisms underlying methamphetamine-induced neurotoxicity and implications for pharmacological treatment. Front Mol Neurosci 2018;11:186. PMID 29915529
341: Zalesky A, Solowij N, Yucel M, et al. Effect of long-term cannabis onpou axonal fibre connectivity. Brain 2012;135(Pt 7):2245-55. PMID 22669080

Contributors

All contributors' financial relationships have been reviewed and mitigated to ensure that this and every other article is free from commercial bias.

Authors

Michael J Schneck MD

Dr. Schneck of Loyola University of Chicago has no relevant financial relationships to disclose.
See Profile
Alexandria Pecoraro MD

Dr. Pecoraro of Loyola University Medical Center has no relevant financial relationships to disclose.
See Profile

Editor

Matthew Lorincz MD PhD

Dr. Lorincz of the University of Michigan has no relevant financial relationships to disclose.
See Profile

Former Authors

John C M Brust MD

Patient Profile

Age range of presentation: 0 month to 65+ years
Sex preponderance: male=female
Heredity: none
Population groups selectively affected: none selectively affected
Occupation groups selectively affected: none selectively affected

This is an article preview.
Start a Free Account
to access the full version.

Nearly 3,000 illustrations, including video clips of neurologic disorders.
Every article is reviewed by our esteemed Editorial Board for accuracy and currency.
Full spectrum of neurology in 1,200 comprehensive articles.
Listen to MedLink on the go with Audio versions of each article.

Questions or Comment?

MedLink®, LLC

3525 Del Mar Heights Rd, Ste 304
San Diego, CA 92130-2122

Toll Free (U.S. + Canada): 800-452-2400

US Number: +1-619-640-4660

Support: service@medlink.com

Editor: editor@medlink.com

ISSN: 2831-9125

Illicit drug use: neurologic complications

Also Relevant

Drug-induced dementia
Drug-induced seizures
Headache associated with illicit drug use
Stroke associated with drug abuse

Clinical Categories

Web References

Alerts and Advisories

FDA approves RiVive™ for emergency treatment of opioid overdose

Illicit drug use: neurologic complications …

Illicit drug use: neurologic complications

Introduction

Overview

Key points

Categories of recreational drugs

Table 1. Categories of Recreational Drugs

Categories of drug use

Table 2. Commonly Used Opioids

Table 3. Commonly Used Psychostimulants

Table 4. Commonly Used Sedatives and Hypnotics

Table 5. Inhalants

Neurologic complications of illicit agents

References

Contributors

Authors

Editor

Former Authors

Patient Profile

This is an article preview.
Start a Free Account
to access the full version.

Questions or Comment?

Also in This Category

Neurogenetics and genetic and genomic testing

Acute traumatic spinal cord injury

Tumors of the skull base

Toxic and nutritional deficiency optic neuropathies

Nystagmus

Third nerve palsy

Brain death/death by neurologic criteria

Outpatient rehabilitation of chronic neurologic conditions

Illicit drug use: neurologic complications

Introduction

Overview

Key points

Categories of recreational drugs

Table 1. Categories of Recreational Drugs

Categories of drug use

Table 2. Commonly Used Opioids

Table 3. Commonly Used Psychostimulants

Table 4. Commonly Used Sedatives and Hypnotics

Table 5. Inhalants

Neurologic complications of illicit agents

References

Contributors

Authors

Editor

Former Authors

Patient Profile

This is an article preview. Start a Free Account to access the full version.

Questions or Comment?

Also in This Category

Neurogenetics and genetic and genomic testing

Acute traumatic spinal cord injury

Tumors of the skull base

Toxic and nutritional deficiency optic neuropathies

Nystagmus

Third nerve palsy

Brain death/death by neurologic criteria

Outpatient rehabilitation of chronic neurologic conditions

This is an article preview.
Start a Free Account
to access the full version.